Liposomal composition, methods and uses thereof
A brain-targeting liposomal composition using PEGylated, pH-sensitive liposomes with specific peptides enhances the delivery of SAG across the blood-brain barrier, improving stem cell differentiation and integration for effective neurodegenerative disease treatment.
Patent Information
- Application Number
- PCT/EP2026/063678
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
Current strategies for treating neurodegenerative diseases face challenges in effectively delivering therapeutic molecules to the brain due to the blood-brain barrier, leading to modest outcomes in stem cell transplantation therapies.
A brain-targeting liposomal composition functionalized with PEGylated, pH-sensitive liposomes and specific peptides (DAS and IKRG) is developed to enhance the delivery of Smoothened Agonist (SAG) across the blood-brain barrier, promoting the differentiation of neural stem cells into mature neurons.
The liposomal composition achieves superior brain accumulation and enhances the integration of transplanted cells, increasing the number of mature neurons and reducing peripheral toxicity, thus improving the effectiveness of stem cell therapies for neurodegenerative diseases.
Smart Images

Figure IMGF000028_0001_TABLE 
Figure IMGF000029_0001_TABLE 
Figure IMGF000030_0001_TABLE
Abstract
Description
D E S C R I P T I O NLIPOSOMAL COMPOSITION, METHODS AND USES THEREOFTECHNICAL FIELD
[0001] The present disclosure relates to the field of pharmaceutical nanotechnology and drug delivery systems. More particularly, the disclosure relates to a brain-targeting liposomal composition comprising at least one therapeutic molecule by encapsulation, adsorption or complexation. The composition is designed to increase the delivery to the brain of the at least one therapeutical molecule, while improving its safety in circulation.BACKGROUND
[0002] Neurodegenerative diseases are increasingly becoming a social and financial burden worldwide as the human lifespan increases. The World Health Organization estimates that 20% of the human population suffers from CNS diseases. Despite the efforts from the scientific community to develop innovative therapies for these diseases, the drug development success rate to treat neurodegenerative diseases remains quite poor. The complexity and heterogeneity of neurodegenerative diseases, associated with the lack of effective early diagnosis biomarkers, and the difficulty to transpose the blood-brain barrier (BBB), are some of the main challenges faced by this research field. Despite the heterogeneity of neurodegenerative diseases, some features are similar and found across these diseases affecting the CNS. One of such characteristics is the extensive neuronal loss found in Alzheimer's disease, Parkinson's disease, and Machado-Joseph disease. This widespread neuronal loss justifies the use of cell replacement strategies, namely through the transplantation of neural stem cells, to recover and rehabilitate the brain tissue and function.
[0003] A considerable amount of work regarding the transplantation of stem cells to restore and rehabilitate brain function has been done in the past few decades focusing on several neurodegenerative diseases, including in Machado-Joseph disease (MJD). Such work demonstrates the potential of these therapies to reverse neurodegeneration, trigger cellular replacement and bystander effects through the production of neurotrophic factors, reduction of neuroinflammation, and overall regulation of brain microenvironment. For example, research has demonstrated the differentiation of transplanted murine neural stem cells (mNSC) into neurons, their survival in the host's brain, and also a reduction in the mRNA levels of pro-inflammatory cytokine interleukin 1 (IL-ip), and increased mRNA levels of Brain-derived Neurotrophic Factor (BDNF) and glutamate receptor 3 (Gria3). Moreover, these cells were able to rescue the number of calbindin-positive neurons, cellular layer thickness, and reducethe number of mutant Ataxin-3 aggregates in the cerebellum of a mouse model of MJD. More recently, it has been demonstrated that human iPSC-derived neuroepithelial stem cells (hNESC) cerebellar transplantation increased levels of BDNF and Nerve Growth Factor (NGF). Also, an activation of neurogenesis was detected after transplantation by increased levels of Musashi 1 (Msil) and Neurogenic Differentiation 1 (NeuroDl). Additionally, the establishment of functional synapses between the transplanted hNESC and the host's brain demonstrates their integration. Their differentiation was confirmed by the expression of neuronal markers microtubule associated protein 2 (MAP2), P3-Tubulin, glial fibrillary acidic protein (GFAP), and SIOOB in hNESC after transplantation. Moreover, evidence indicates that cell therapy is safe, and its benefits surpass the risks involved.
[0004] The migration, differentiation, and integration of neural stem cells are cellular processes mediated by a precisely organized sequence of molecules that guide the stem cells through these different cellular pathways during neurogenesis. Although neurogenesis is still present in the adult brain, this process extensively declines in an age-dependent manner. Nevertheless, some interesting work demonstrated that neurogenesis can be artificially modulated and stimulated by small-molecule drugs, such as fasudil, resveratrol, sildenafil, simvastatin, metformin, ketamine, and liraglutide. These small-molecule drugs have been demonstrated to stimulate neurogenesis in vivo by the increase in the proliferation / migration of neural progenitor cells, enhanced axonal growth, synaptogenesis and innervation, and greater expression of mature neuronal markers, such as NeuN, resulting in symptom alleviation in several mouse models of brain diseases. Additionally, Ibuprofen also enhanced neural differentiation in vitro and in vivo. Although these results indicate that pharmacological modulation of neural stem cells for transplantation is possible, the outcomes are still quite modest. Therefore, there is a need to identify small-molecule drugs that more efficiently induce hNESC differentiation and develop safe strategies for their delivery.
[0005] Liposomes are lipid-based structures composed of a phospholipid bilayer with an aqueous core with size in nano to microscale, and able to carry small-molecule drugs, peptides, or nucleic acids, serving as delivery vehicles in nanomedicines. Additionally, liposomes production is usually cost-effective, reproducible, and allows scalability. Such nanomedicines are prone to be administrated in minimally invasive ways (e.g. intravenous administration) and are set to be a promising approach to overcome several therapeutic limitations. For example, after administration, small molecules, peptides or nucleic acids are subjected to quick metabolization and elimination from the body, causing no therapeutic effect or a need to increase dosage that may lead to toxic side effects. By encapsulation in liposomes, such drugs / molecules are protected from these processes, increasing their half-life in systemic circulation, raising the probability to reach the target tissue, and eliminating the need to increase drug dosage. Hence, in order to further reduce toxicity and immunogenicity, liposomes'composition should be preferentially biocompatible and biodegradable to ensure its safety, namely when used in long-term therapies. Interestingly, pH-sensitive linkers, such as hydrazone, in the lipid structure can also be employed to further enhance the liposomes' ability to deliver their cargo after internalization. Furthermore, liposomes' surface chemistry can be tailored to improve biodistribution. One of such manipulations is the surface functionalization using hydrophilic polymers, like polyethylene glycol (PEG), chitosan, or hyperbranched polyglycerol. Specifically, PEGylated liposomes are liposomes that present PEG chains at their surface attached to their lipid structure. This strategy creates a "cloud" of water molecules on their surface that reduces the opsonization effect and, consequently, decreases the liposomes' elimination from circulation resulting in increased circulation times, and higher probability to reach the target cells / organs. Moreover, liposomes' surface can be functionalized with targeting ligands that enable them to be directed to specific cells or tissues, enhancing their accumulation in these sites, while reducing off-target effects.
[0006] Document Xu J. e Chau Y., Polymeric nanoparticles decorated with BDNF-derived peptide for neuron-targeted delivery of PTEN inhibitor, European Journal of Pharmaceutical Sciences, vol. 124, pp.37-45, 2018 discloses targeted polymeric drug delivery systems comprising the IKRG ligand for delivery to neurons of the peripheral nervous system, in particular dorsal root ganglion (DRG) neurons.
[0007] Document Moreira et al., Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands, Journal of Nanobiotechnology, vol. 22, 2024 provides a review of the various targeting ligands used to direct nanoparticles to specific brain cell types, including ligands for neurons, astrocytes, oligodendrocytes, microglia, neural stem cells and endothelial cells of the bloodbrain barrier.
[0008] Document CN117205175A discloses a plant exosome-liposome composite targeted nanoparticle drug delivery system, as well as a method for preparing the same and the use thereof.
[0009] Document Islam et al., Peptide based drug delivery systems to the brain, Nano Express, vol. 1, n.91, 2020 provides a review on self-assembled peptides, shuttle peptides and nanoparticles drug delivery systems decorated / conjugated with peptides for brain penetration.
[0010] Document Fu et al., Targeted transport of nanocarriers into brain for theranosis with rabies virus glycoprotein-derived peptide, Materials Science and Engineering: C, vol. 87, pp. 155-166, 2018 provides a review of nanocarriers functionalised with peptide derivatives of rabies virus glycoprotein for transport across the blood-brain barrier and targeted delivery into the brain.
[0011] Document Ghorai et al., Cell-Penetrating and Targeted Peptides Delivery Systems as Potential Pharmaceutical Carriers for Enhanced Delivery across the Blood-Brain Barrier (BBB), Pharmaceutics, vol.15, n.97 , 2023 provides a review of cell-penetrating peptides (CPPs) and homing / targeted peptides as pharmaceutical carriers for transport across the blood-brain barrier.
[0012] There is an unmet need for providing improved strategies capable of enhancing the differentiation of stem cells within the brain in order to promote the regeneration of neural tissue and support the development of effective treatments for neurodegenerative diseases.
[0013] These facts are disclosed in order to illustrate the technical problem addressed by the present disclosure.GENERAL DESCRIPTION
[0014] The present disclosure relates to a brain-targeting liposome composition comprising at least one therapeutic molecule by encapsulation, adsorption or complexation. The composition is designed to increase the delivery to the brain of the at least one therapeutical molecule, while improving its safety in circulation.
[0015] The present disclosure relates to a brain-targeting liposomal delivery system designed to enhance the effectiveness of neural stem cell transplantation for neurodegenerative diseases. The PEGylated, pH-sensitive liposomes of the present disclosure are functionalized with specific peptides, preferably DAS and IKRG, to improve drug delivery across the blood-brain barrier while minimizing peripheral toxicity. These nanocarriers were used to encapsulate Smoothened Agonist (SAG), a small molecule found to significantly boost the differentiation of stem cells into mature neurons both in vitro and in vivo. The disclosed experimental results demonstrated that these targeted liposomes achieved superior brain accumulation in mouse models and more effectively promoted the integration of transplanted cells into the brain. Overall, the source highlights a nanotechnology-based co-therapy that addresses current limitations in regenerative medicine and pharmacological brain targeting.
[0016] Surprisingly, the liposomal composition of the present disclosure comprising the PEGylated, pH-sensitive and brain-targeted liposomes encapsulating SAG demonstrated in vitro the ability to enhance hNESC neuronal differentiation by increasing the number of NeuN-positive cells. In vivo, the brain-targeted liposomes showed 22% and 29% accumulation in the mice brain using the DAS (SEQ. ID NO 1) ligand and IKRG (SEQ. ID NO 2) ligand, respectively. Reduced accumulation in peripheral organs for Lipo-DAS and Lipo-IKRG was observed compared to non-targeted liposomes. Finally, DAS-targeted liposomes encapsulating SAG promoted graft survival of murine neural stem cells (mNSC) in MJD-transgenic mice and enhanced mNSC differentiation into NeuN-positive mature neurons observed 6 weeks after transplantation.
[0017] Neurodegenerative diseases are increasing in our aging society and are characterized by vast neuronal death. Cell therapy can alleviate the outcome of neurodegenerative diseases by replacing the damaged and dead cells and produce neurotrophic factors. Nonetheless, the lack of migration, differentiation, and integration into the host's brain hampers further positive outcomes using this strategy. The use of small-molecule drugs that can stimulate molecular and cellular pathways related to neurodevelopment holds the promise to enhance migration and differentiation of stem cells after brain transplantation.
[0018] In the context of the present disclosure, small-molecule drugs able to modulate stem cell differentiation pathways and selected Ibuprofen, Smoothened agonist (SAG), Salbutamol, and Folic Acid were studied to test their ability to induce human iPSC-derived NESC (hNESC) differentiation in vitro. These drugs revealed no major cytotoxicity evaluated by resazurin reduction and fluorescein diacetate assays. Most interestingly, after treatment with SAG, hNESC revealed an increase in the mRNA levels of neuronal markers microtubule associated protein 2 (MAP2) and P3-tubulin (TUBB) and a two-fold increase in the protein levels of MAP2 and P3-tubulin compared to non-treated control hNESC. In vivo, SAG promoted a 20-fold increase in the number of graft-derived mature neuron marker neuronal nuclear protein (NeuN)-positive cells in hNESC-transplanted animals compared to non-treated hNESC-grafted animals.
[0019] Furthermore, in the context of the present disclosure, stealth (PEGylated), pH-sensitive, and brain-targeted liposomes were developed for SAG encapsulation. The brain-targeting ligands DAS (SEQ. ID NO 1), IKRG (SEQ. ID NO 2), and rabies virus glycoprotein with 9 arginines (RVG-9r, SEQ. ID NO 3) were tested in vitro and found to target hNESC and hNESC-derived neural cultures. DAS (SEQ. ID NO 1) and IKRG (SEQ. ID NO 2) were selected and integrated in the PEGylated liposomes by post-insertion method. SAG was encapsulated in the stealth liposomes by pH gradient, obtaining encapsulation efficiency values of 95.6 ± 1.8%, 86.1 ± 12.4%, and 82.5 ± 6.7% for liposomes targeted with DAS (Lipo-DAS), IKRG (Lipo-IKRG), or non-targeted (Lipo-NT), respectively. The mean size of the liposomes was 126.5 ± 9.7 nm, 125.8 ± 9.6 nm, and 134.95 ± 4.2 nm for Lipo-DAS, Lipo-IKRG, and Lipo-NT, respectively. Polydispersity index (PDI) was 0.135 ± 0.09, 0.236 ± 0.05, and 0.16 ± 0.10 for Lipo-DAS, Lipo-IKRG, and Lipo-NT, respectively. Liposomes zeta potential was -9.18 ± 1.25 mV, -10.77 ± 2.04 mV, and -12,42 ± 3,15 mV for Lipo-DAS, Lipo-IKRG, and Lipo-NT, respectively.
[0020] The present disclosure relates to a liposomal composition comprising a plurality of pH-sensitive liposomes, each liposome comprising:an outer lipidic shell, wherein the outer lipidic shell comprises a mixture of: distearoylphosphatidylcholine (DSPC), cholesterol (CHOL), and at least a mixture of two pharmaceutical acceptable pH-sensitive lipids;an aqueous inner core comprising an active compound;at least one brain-targeting molecule having at least 90% sequence identity to at least one of the following sequences: SEQ ID NO: 1, SEQ ID NO: 1, or mixtures thereof;wherein said brain-targeting molecule is bound to the surface of the outer lipidic shell; wherein the plurality of pH-sensitive liposomes releases the active compound at a pH in the range of 5.0 to 6.5.
[0021] In an embodiment, the plurality of pH-sensitive liposomes releases the active compound at a pH in the range of 5.0 to 5.5.
[0022] In an embodiment, the at least a mixture of two pharmaceutical acceptable pH sensitive lipids is a mixture of l,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE) and l,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Hydrazone] Polyethylene Glycol 2000 (DSPE-Hz-PEG2000).
[0023] An aspect of the present disclosure relates to a liposomal composition comprising a plurality of pH-sensitive liposomes, each liposome comprising:an outer lipidic shell, wherein the outer lipidic shell comprises l,2-Dioleoyl-sn-Glycero-3- Phosphoethanolamine (DOPE), l,2-Distearoyl-sn-Glycero-3- Phosphoethanolamine-N-[Hydrazone] Polyethylene Glycol 2000 (DSPE-Hz-PEG2000), distearoylphosphatidylcholine (DSPC), and cholesterol (CHOL);an aqueous inner core comprising an active compound, wherein said active compound is preferably an active pharmaceutical compound;at least one brain-targeting molecule comprising an amino acid sequence at least 90% identical to at least one of the following sequences: SEQ ID NO: 1, or SEQ ID NO: 2; andwherein the at least one brain-targeting molecule is bound to the surface of the outer lipidic shell; namely the at least one brain-targeting molecule interacts with receptors, proteins, and / or glycoproteins overexpressed or specifically expressed on the cell surface of a specific cellular target preferably the tropomyosin receptor kinase B (TrkB) and / or the Nicotinic acetylcholine receptor on the surface of blood brain barrier cells, neural stem cells, neuroepithelial stem cells, neural progenitor cells, cancer stem cells, neurons, astrocytes, oligodendrocytes, microglia, or combinations thereof);and wherein the pH-sensitive liposomes are sensitive within the pH range of 5.0 to 6.5.
[0024] In an embodiment, the active compound may be incorporated in the aqueous inner core by encapsulation, adsorption and / or complexation.
[0025] In an embodiment, the brain-targeting molecule is selected from a list consisting of: a peptide, a polypeptide, an antibody, (namely a polyclonal antibody, a monoclonal antibody, an antibody fragment,a humanized antibody, a recombinant antibody, a recombinant human antibody, a nanobody), aptamer, protein, cell surface ligand, or combinations thereof.
[0026] In an embodiment, the brain-targeting molecule is able to interact with specific cell surface molecules selected from a list consisting of: receptors, proteins, glycoproteins, or combinations thereof.
[0027] In an embodiment, the cell is selected from a list consisting of: blood brain barrier cells, neural stem cells, neuroepithelial stem cells, neural progenitor cells, cancer stem cells, neurons, astrocytes, oligodendrocytes, microglia, or combinations thereof.
[0028] In an embodiment, the outer lipidic shell forms at least one lamella surrounding the aqueous inner core and thereby defines an outer aqueous phase.
[0029] In an embodiment, the active compound is smoothened agonist, namely from Calbiochem ® (CAS number 912545-86-9).
[0030] In an embodiment, the brain-targeting molecule is bound to the outer lipidic shell through a covalent, an ionic, or hydrogen chemical bond.
[0031] In an embodiment, the brain-targeting molecule is selected from a list consisting of: peptide, polypeptide, antibody, aptamer, protein, cell surface ligand, or combinations thereof.
[0032] In an embodiment, the peptide comprises an aminoacid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1, or SEQ ID NO: 2.
[0033] In an embodiment, a molar ratio (%) of the DOPE, DSPC, CHOL, and DSPE-Hz-PEG2000 is of 37:22:33:8 (DOPE:DSPC:CHOL:DSPE-Hz-PEG2000).
[0034] In an embodiment, the plurality of pH-sensitive liposomes is dispersed in an aqueous phase.
[0035] In an embodiment, the active compound is selected from a list consisting of: a therapeutic molecule, a small molecule, a nucleic acid, a plasmid, an antisense oligonucleotide, a chemical compound, a virus, a protein, a peptide, a radioisotope, a radiopharmaceutical, and combinations thereof.
[0036] In an embodiment, the active compound is selected from a list consisting of: a chemotherapy drug, a hormonal therapeutic agent, an immunotherapeutic agent, an antiviral drug, an antiinflammatory drug, an antidepressant, an antibiotic, an anticoagulant, an antidiabetic, an analgesic, an anticancer agent, an antiepileptic, an antipsychotic, an antispasmodic, a cardiovascular agent, a depressant agent, a sedative, a stimulant agent, a painkiller agent, an antipyretic, a vasodilator, an anti-angiogenic, a cytovascular agent, a signal transduction inhibitor, a tyrosine kinase inhibitor, an anti-arrhythmic compound, a hormone, a vasoconstrictor, a steroid, or combinations thereof.
[0037] In an embodiment, the active compound is smoothened agonist (CAS number 912545-86-9).
[0038] In an embodiment, the active compound Smoothened Agonist (CAS number 912545-86-9) is incorporated by, but not limited to pH gradient method.
[0039] In an embodiment, the composition further comprises a gene therapy vector, and / or a contrast agent for imaging.
[0040] In an embodiment, the liposome further comprises a linker between the outer lipidic shell and the at least one brain-targeting molecule; preferably wherein the linker is a covalent linker like hydrazone linkage and disulfide linkage, and / or a hydrophobic anchor like stearyl chains and PEG spacers.
[0041] In an embodiment, the linker may be positioned between the liposome and the brain-targeting molecule(s) to avoid hindrance on the interaction between the brain-targeting molecule(s) and its target(s).
[0042] In an embodiment, a chemical bound sensitive to external physicochemical alterations may be positioned between the liposome and the linker to shed the linker from the liposome and enhance cargo delivery.
[0043] In an embodiment, the liposome further comprises a structural lipid selected from a list consisting of: cholestenol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-2'-hydroxybutyl ether, dipalmitoylphosphatidylcholine (DPPG), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), palmitoyloleyolphosphatidylglycerol (POPG), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidyiethanolamine (DMPE), dielaidoylphosphatidyiethanolamine (DEPE), distearoylphosphatidyiethanolamine (DSPE), stearoyloleoylphosphatidyiethanolamine (SOPE), egg phosphatidylcholine (EPC), or combinations thereof.
[0044] In an embodiment, the outer lipidic shell further comprises at least one lipid conjugated to a polymer selected from a list consisting of: poly(acryl amide), poly(vinyl pyrrolidone), poly(acryloyl morpholine), poly(2-ethyl- 2-oxazoline), poly(2-methyl-oxazoline), phosphatidyl polyglycerol, polyvinyl alcohol, polysaccharide, polyethylene glycol (PEG), polyethylene glycol containing a copolymer, or combinations thereof; preferably polyethylene glycol (PEG).
[0045] In an embodiment, the at least one conjugated lipid is conjugated to a polyethylene glycol polymer such as: PEG-diacylglycerol (DAG), PEG-dialkyloxypropyl (DAA), PEG-ceramide (Cer), PEG-phosphatidylethanolamine, PEG-1, 2-distearoyl-snglycero-3-phosphoethanolamine (DSPE), PEG-1-methyl-4-(cis-9- dioleyl) methyl-pyridinium chloride (PEG-SAINT) or combinations thereof.
[0046] In an embodiment, the plurality of pH-sensitive liposomes comprises:40-90 mol% of a structural lipid; and1-60 mol% of a combination of DOPE and DSPE-Hz-PEG2000; and10-90 mol% of DSPC; and0.1-10 mol% of the at least one brain-targeting molecule;relative to the total content of a liposome.
[0047] In an embodiment, the average molecular weight of the polyethylene glycol polymer conjugated to the lipid ranges from 550 daltons to 10000 daltons.
[0048] In an embodiment, the drug encapsulating efficiency is at least 80 % (w / w) relative to the total of lipid content.
[0049] In an embodiment, the outer lipidic shell is a phospholipid bilayer shell.
[0050] In an embodiment, the composition is an aqueous colloidal suspension.
[0051] In an embodiment, the liposomes have a zeta potential at 25 °C ranging from -11 mV to -9 mV, measured by electrophoretic light scattering (ELS).
[0052] In an embodiment, the liposomes have a size ranging from 125 nm to 135 nm, measured by nanoparticle tracking analysis (NTA).
[0053] In an embodiment, the liposomes have a polydispersity index lower than 0.3, measured by dynamic light scattering (DLS); preferably ranging from 0.12 to 0.25.
[0054] Another aspect of the present disclosure further relates to the use of the liposomal composition in medicine.
[0055] In an embodiment, the composition is for use in the treatment of neurodegenerative diseases and injuries, demyelinating diseases, cardiovascular diseases, skin and wound repair, neurodevelopmental disorders, cancer, or developmental defects.
[0056] In an embodiment, the composition is for use in the treatment of protein misfolding disorders, protein aggregation disorders, tauopathies, synucleinopathies, polyglutamine disorders, amyloid-related neurodegenerative disorders, motor neuron degenerative diseases, dementias associated with neurodegeneration, basal ganglia neurodegenerative disorders, cerebellar neurodegenerative disorders, movement-related neurodegenerative disorders, age-related neurodegenerative disorders, neuroinflammatory neurodegenerative disorders, mitochondrial dysfunction-associated neurodegenerative disorders, lysosomal dysfunction-associated neurodegenerative disorders, genetic neurodegenerative disorders of the central nervous system, progressive neurodegenerative disordersaffecting the brain, central nervous system degenerative diseases, chronic neurodegenerative disorders, or adult-onset neurodegenerative diseases.
[0057] In an embodiment, the composition is for use in the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, frontotemporal dementia, multiple system atrophy, dementia with Lewy bodies, spinocerebellar ataxias, Machado-Joseph disease, progressive supranuclear palsy, or corticobasal degeneration.
[0058] In an embodiment, the composition is administered with at least one more active compound.
[0059] In an embodiment, the at least one more active compound is selected from a list consisting of: neuroprotective agents, anti-inflammatory agents, antioxidant agents, anti-apoptotic agents, protein aggregation inhibitors, tau phosphorylation inhibitors, amyloid-beta targeting agents, alpha-synuclein targeting agents, cholinergic agents, glutamatergic modulators, dopaminergic agents, mitochondrial stabilizers, autophagy inducers, gene expression modulators, nucleic acids, biologies, or combinations thereof.
[0060] In an embodiment, the composition is administered at least once a month.
[0061] In an embodiment, the composition is administered at least once a day.
[0062] In an embodiment, the composition is administered every other day for a period of at least 5 days.
[0063] In an embodiment, the composition is administered to improve cell therapy outcome.
[0064] In an embodiment, the composition is administered to improve engraftment of neural stem cells, and / or neural stem cells, and / or neuroepithelial stem cells, and / or neural progenitor cells.
[0065] In an embodiment, the composition is administered to improve treatment of cancer stem cells, preferably to improve cell differentiation and / or cell death and / or cell arrest.
[0066] Another aspect of the present disclosure further relates to a method for obtaining the plurality of pH-sensitive liposomes of the composition of the present disclosure, comprising the following steps:providing a lipidic mixture composed of DOPE, DSPC, CHOL, and DSPE-Hz-PEG, preferably in a molar ratio of 37:22:33:8 (DOPE:DSPC:CHOL:DSPE-Hz-PEG);dissolving the lipidic mixture in ethanol and forming a lipid film by solvent evaporation; hydrating the obtained lipid film with an ammonium sulfate solution to form liposomes; encapsulating the active compound into the liposomes obtained in the previous step, at a molar ratio of 1:16 (active compound:total lipid content of the liposomes obtained);post-inserting the brain-targeting molecule coupled to DSPE-PEG2000-micelles into the liposomes in an amount of 4 mol%, relative to the total lipid content of the liposomes;obtaining the plurality of pH-sensitive liposomes.
[0067] Another aspect of the present disclosure further relates to a method of treating a neurodegenerative disease, an injury, a demyelinating disease, a cardiovascular disease, a skin and wound repair, a neurodevelopmental disorder, cancer, or a developmental defect, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition of the present disclosure.
[0068] Another aspect of the present disclosure further relates to the use of the composition of the present disclosure in the manufacture of a medicament for the treatment of a neurodegenerative disease, an injury, a demyelinating disease, a cardiovascular disease, skin and wound repair, a neurodevelopmental disorder, cancer, or a developmental defect.
[0069] Another aspect of the present disclosure further relates to the use of smoothened agonist (CAS number 912545-86-9) in the treatment of neurodegenerative diseases.
[0070] The term "pH-sensitive" whenever used in this document is intended to refer to a property of the liposomes whereby the liposomal membrane undergoes a detectable physicochemical and / or structural change when exposed to a weakly acidic environment, relative to physiological pH, as a result of the presence of one or more pH-responsive lipid constituents in the lipidic shell, thereby promoting destabilisation of the liposome and increased release of the encapsulated cargo. In the context of the present disclosure, a "pH-sensitive liposome" is a liposome that remains comparatively stable at physiological pH and becomes destabilised at weakly acidic pH, preferably at a pH of 5.0 to 6.5, more preferably at about pH 5.5, such that release of the encapsulated cargo is increased under said weakly acidic conditions.
[0071] In an embodiment, the pH-sensitivity of the liposomes of the present disclosure is conferred by the presence, in the lipidic shell, of at least one acid-labile lipid, preferably a hydrazone-containing PEG-lipid, more preferably DSPE-Hydrazone-PEG2000, which undergoes cleavage under weakly acidic conditions, thereby reducing the stabilising effect of the PEG moiety and promoting liposomal destabilisation and cargo release under weakly acidic conditions.
[0072] In an embodiment, the liposomes of the present disclosure are pH-sensitive liposomes configured to remain substantially stable under physiological conditions and to become destabilised upon exposure to weakly acidic environments, such as those encountered in endosomal compartments after cellular internalisation. Such pH sensitivity is conferred by the presence of a pH-responsive lipid component within the lipidic shell, preferably a hydrazone-containing PEG-lipid, more preferably DSPE-Hz-PEG2000. Upon exposure to acidic pH, cleavage of the acid-labile hydrazone bond leads to de-PEGylation of the liposome surface, thereby reducing steric stabilisation and promoting destabilisation of the liposomal membrane and release of the encapsulated cargo.
[0073] In an embodiment, the pH-sensitive effect provided by the liposomes of the present disclosure is further conferred by the presence of DOPE. DOPE is a pH-sensitive lipid that although not itself necessarily a acid-cleavable constituent, at acidic pH it undergoes a transition from a bilayer to hexagonal configuration and this tendency to favour non-bilayer phases and membrane fusion contributes to liposome destabilisation once the PEG shielding has been reduced or removed under acidic conditions. Thus, DSPE-Hz-PEG2000 is regarded as the principal pH-responsive constituent, whereas DOPE is regarded as a membrane-destabilising co-constituent that enhances cargo release to cytoplasm following acid-triggered de-PEGylation.
[0074] In an embodiment, the liposomes of the present disclosure comprise one or more PEGylated lipids in the lipidic shell. PEGylation contributes to steric stabilisation of the liposomes, reduces aggregation, improves colloidal stability, prolongs circulation time, and contributes to stealth behaviour in vivo by reducing non-specific interactions with biological components. In preferred embodiments, the PEGylated lipid comprises DSPE-PEG2000 and / or DSPE-Hz-PEG2000.
[0075] The term "brain-targeting molecule" whenever used in this document is intended to refer to a targeting ligand used to direct the liposomes of the present disclosure to receptors, proteins, and / or glycoproteins overexpressed or specifically expressed on the cell surface of a specific cellular target.
[0076] In an embodiment, the "brain-targeting molecule" interacts with the tropomyosin receptor kinase B (TrkB) and / or the nicotinic acetylcholine receptor present on the surface of blood brain barrier cells, neural stem cells, neuroepithelial stem cells, neural progenitor cells, cancer stem cells, neurons, astrocytes, oligodendrocytes, microglia, or combinations thereof. In an embodiment, the liposomes of the present disclosure are functionalized with at least one brain-targeting molecule that enables them to be directed to specific cells or tissues, enhancing their accumulation in these sites, while reducing off-target effects; preferably the brain-targeting molecule comprises an amino acid sequence at least 90% identical to at least one of the following sequences of the present disclosure: SEQ ID NO: 1, or SEQ ID NO: 2.BRIEF DESCRIPTION OF THE DRAWINGS
[0077] The following figures provide preferred embodiments for illustrating the disclosure and should not be seen as limiting the scope of invention.
[0078] Figure 1: Assessment of the cell toxicity of differentiation-inducing drugs Ibuprofen, Smoothened Agonist, Salbutamol and Folic Acid and their impact in mRNA levels of neuronal markers(MAP2 and TUBBS) and their molecular target genes. Cell viability of hNESC after 6 days incubation with (A-B) Ibuprofen at the concentrations of 1 mM, 500 pM, 50 pM and 5 pM; (C-D) Smoothened Agonist at the concentrations of 50 nM, 5 nM, 1 nM and 0.5 nM; (E-F) Salbutamol at the concentrations of 100 pM, 50 pM, 5 pM and 0.5 pM; (G-H) Folic Acid at the concentrations of 100 pM, 10 pM, 1 pM and 0.1 pM was evaluated by (A, C, E, G) resazurin reduction assay and (B.l, B.2 D.l, D.2, F.l, F.2, H.l, H.2) fluorescein diacetate (FDA) assay. (B.l, D.l, F.l, H.l) Representative widefield fluorescence microscopy images of FDA fluorescence signal in hNESC. (B.2, D.2, F.2, H.2) Quantification of the cell viability by (A, C, E, G) resazurin reduction assay normalized for controls (non-treated hNESC, CNT) and by FDA assay normalized for average fluorescence intensity of controls (non-treated hNESC, CNT). mRNA levels quantification of neuronal markers (TUBBS and MAP2) and drugs' molecular target genes (PTGS2 for Ibuprofen, GLI1 for Smoothened Agonist, FGF20 for Salbutamol, and NOTCH1 for Folic Acid) in hNESC after 6 days incubation with (I) Ibuprofen at the concentrations of 500 pM, 50 pM and 5 pM, (J) Smoothened Agonist at the concentrations of 50 nM, 5 nM and 0.5 nM, (K) Salbutamol at the concentrations of 100 pM, 50 pM, 5 pM and 0.5 pM, or (L) Folic Acid at the concentrations of 100 pM, 10 pM, 1 pM and 0.1 pM, evaluated by RT-qPCR normalized for housekeeping (GAPDH). Data are presented as mean ± SEM compared to control (non-treated hNESC); *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; Unpaired t-test with Welch's correction; n=5 independent experiments; Scale bars: 50 pm.
[0080] Figure 2: Assessment of Ibuprofen, Folic Acid, Salbutamol, and Smoothened Agonist potential to induce hNESC differentiation in vitro. (A-T) Immunofluorescence widefield microscopy images of hNESC exhibiting neuronal markers P3-tubulin (red) and MAP2 (white), and glial marker GFAP (green) after a 6 days treatment with (E-H) 500 pM Ibuprofen, (l-L) 100 pM Folic Acid, (M-P) 100 pM Salbutamol, (Q-T) and 50 nM Smoothened Agonist, compared to Control (non-treated hNESC). Representative images of 3 independent experiments; DAPI: blue; scale bars: 50 pm. (U-V) hNESC treated with 50 nM of Smoothened Agonist for 6 days analyzed for neuronal markers P3-tubulin and MAP2, astrocyte marker GFAP, the molecular target of Smoothened Agonist (GUI), and housekeeping Tubulin protein expression. (U) Representative Western-Blot images of treated and non-treated (CNT) hNESC, and (V) protein levels quantification normalized for housekeeping Tubulin and compared to non-treated (CNT) hNESC. Data are expressed as mean ± SEM compared to control (non-treated hNESC); **p < 0.01; Unpaired t-test with Welch's correction; n=5 independent experiments.
[0082] Figure 3: Assessment of the potential of SAG to enhance cellular differentiation of hNESC transplanted in the cerebellum of NOD.SCID mice. To evaluate the ability of SAG to enhance hNESC differentiation in vivo, GFP-expressing hNESC (hNESC-GFP) were transplanted in the cerebellum of 4-5 weeks old NOD.SCID mice. (A, C-H) Mice without further treatment (control), or (B, l-N) also treatedwith 3 intraperitoneal injections of SAG 30 mg / kg, every other day starting 7 days after cell transplantation (SAG 30 mg / kg) presented hNESC-GFP 6 weeks after transplantation. Representative fluorescence images illustrating the presence of hNESC-GFP (green) in cerebellum of (A) control mice, and (B) mice treated with SAG 30 mg / kg. Representative immunofluorescence confocal microscopy images of (C, E, I, K) astroglial marker GFAP (purple), and (D, F, J, L) neuronal marker MAP2 (red) in control mice or animals treated with SAG 30 mg / kg. Images show that six weeks after cell transplantation, control and SAG treated human iPSC-derived NESC grafts have GFAP-positive glial cells and MAP2-positive neurons illustrated by the colocalization between GFP and GFAP and MAP2, respectively. DAPI: blue, n=3 mice / group, scale bars: (A-B) 200 pm, (C-J) 50 pm.
[0084] Figure 4: Quantification of hNESC differentiated into neurons and astrocytes in control and SAG-treated mice. Differentiation of hNESC assessed by colocalization of hNESC-GFP (green) with neuronal marker NeuN (red), and astrocytes marker SOX9 (purple), in control mice or animals treated with SAG 30 mg / kg. Representative immunofluorescence confocal microscopy images of (A, C, G, I, N, R) neuronal marker NeuN (red), and (B, D, H, J, O, S) astroglial marker SOX9 (purple / white) in control mice or animals treated with SAG 30 mg / kg every other day starting 7 days after cell transplantation (SAG 30 mg / kg). Images show that six weeks after cell transplantation, control and SAG treated human iPSC-derived NESC grafts have SOX9-positive glial cells and NeuN-positive neurons illustrated by the colocalization between GFP and SOX9 or NeuN, respectively. DAPI: blue, n=3 mice / group, scale bars: (A-H) 50 pm, (M-T) 100 pm. Percentage of (U) astrocytes (SOX9+ cells) and (V) differentiated neurons (NeuN+ cells) co-localized with hNESC-GFP transplanted into control (CNT) and SAG 30 mg / kg treated animals at 6 weeks post-transplantation. Data are expressed as mean ± SEM compared to control (nontreated animals, CNT); **p < 0.01; Unpaired t-test with Welch's correction; n=3 animals per group.
[0086] Figure 5: Evaluation of brain targeting ligands internalization, liposomes pH sensitivity, and cargo release. (A-L) Representative immunofluorescence confocal microscopy images of FITC (free-FITC), FITC-tagged (green) ligands IKRG (IKRG-FITC), DAS (DAS-FITC), and RVG-r9 (RVG-r9-FITC) incubated with (A-D) hNESC, (E-H) hNESC-derived neural cultures, and (l-L) hNESC in an in vitro BBB model; DAPI: blue; scale bar: 10 pm. (M) Ligands internalization quantification given by fluorescence intensity (RFU) observed for IKRG-FITC, DAS-FITC and RVG-r9-FITC incubated with hNESC, hNESC-derived neural cultures, and hNESC in an in vitro BBB model compared with the signal obtained after incubation with FITC (free-FITC); RFU: relative fluorescence units; *p < 0.05, **p < 0.01, and ****p < 0.0001; data are expressed as mean ± SEM; Ordinary one-way ANOVA with Tukey's multiple comparisons test; hNESC: n=5; Neurons: n=3; In vitro BBB model: n=9. (N) Quantification of the liposomes' pH-sensitivity given by rhodamine B release (%); n=3; data are expressed as mean ± SEM. (O-T) Representative immunofluorescence confocal microscopy images of (O-Q) control hNESC (non-treated), and (R-T)hNESC incubated with Lipo-IKRG RhB, rhodamine B (red) loaded liposomes targeted with IKRG-FITC (green); n=3 independent experiments; scale bar: 10 pm.
[0088] Figure 6: Liposomal ability to deliver efficiently their cargo in vitro. hNESC incubated with liposomes loaded with rhodamine B (red) targeted with DAS (Lipo-DAS RhB), IKRG (Lipo-IKRG RhB), or non-targeted (Lipo-NT RhB) at 4°C or 37°C. Representative immunofluorescence confocal microscopy images of (A-D) control hNESC (non-treated), hNESC incubated with (E-H) non-targeted liposomes loaded with rhodamine B (Lipo-NT RhB), (l-L) DAS-targeted liposomes loaded with rhodamine B (Lipo-DAS RhB), and (M-P) IKRG-targeted liposomes loaded with rhodamine B (Lipo-IKRG RhB) at 37°C or 4°C. DAPI: blue. Scale bars: 10 pm. (Q) Representative histograms of hNESC incubated with Lipo-DAS RhB, Lipo-IKRG RhB, or Lipo-NT RhB for 4 hours compared to non-treated control hNESC and evaluated by flow cytometry. (R) Flow cytometry quantification of the percentage of rhodamine-positive cells after 4 hours incubation with Lipo-DAS RhB, Lipo-IKRG RhB, or Lipo-NT RhB at 4°C or 37°C. Results are presented as mean ± SEM compared to the baseline relative fluorescence obtained for non-treated cells. Unpaired t-test with Welch's correction; ***p < 0.001; n.s.: not statistically significant; n=4 independent experiments.
[0090] Figure 7: Assessment of the cell differentiation ability of targeted liposomes carrying SAG. (A-L) Immunofluorescence images of hNESC after 6 days liposomes incubation, with 2 administrations (at day 0 and day 3) of liposomes targeted with DAS (Lipo-DAS SAG) or IKRG (Lipo-IKRG SAG) compared to control (non-treated hNESC) exhibiting neuronal markers P3-tubulin (red) and MAP2 (white), and glial marker GFAP (green). Representative images of 4 independent experiments. DAPI: blue. Scale bars: 10 pm. The impact of Lipo-DAS SAG or Lipo-IKRG SAG in hNESC differentiation was analyzed through (M, P) TUBB3, MAP2, and GLI1 mRNA levels assessed by RT-qPCR, normalized for housekeeping gene GAPDH, and (N-O, Q-R) protein levels of neuronal markers P3-tubulin and MAP2, and the molecular targeted of SAG, GLI1 assessed by Western-Blot, normalized for housekeeping protein Tubulin, after (M-O) 6 days incubation with 2 administrations (at day 0 and day 3), or (P-R) 4 weeks incubation, with one weekly administration, compared to non-treated control hNESC. (S-X) Representative immunofluorescence images of the expression of mature nuclear neuronal marker NeuN (red) by immunocytochemistry after 4 weeks incubation, with one weekly administration of liposomes targeted with DAS (Lipo-DAS SAG) or IKRG (Lipo-IKRG SAG) loaded with Smoothened Agonist compared to control (non-treated hNESC). DAPI: blue. Scale bars: 50 pm. (Y) Quantification of the percentage of NeuN-positive cells after 4 weeks incubation, with one weekly administration of Lipo-DAS SAG or Lipo-IKRG SAG compared to control (non-treated hNESC). Data are presented as mean ± SEM, unpaired t-test with Welch's correction; *p < 0.05, **p < 0.01; n=4-5 independent experiments.
[0092] Figure 8: Biodistribution of targeted and non-targeted liposomes. Wild-type and transgenic MJD mice were intravenously injected through tail vein injection with liposomes loaded with indocyanine green (ICG) and DAS- or IKRG-targeted (Lipo-ICG DAS or Lipo-ICG IKRG, respectively), or non-targeted (Lipo-ICG NT). Several time points after injection (namely, 15 min, 30 min, lh, 3h, 6h or 24h), near infrared (NIR) images were obtained for the injected animals and non-injected controls (CNT) for baseline signal detection using an IVIS Lumina equipment. (A-D) Representative images of NIR images obtained for the conditions analyzed. (E-G) Fold increase in NIR average radiant efficiency compared to non-injected animals baseline signal during the time points acquired. Fold increase in NIR average radiance efficiency of the (E) total animals, wild-type and MJD transgenic; n=8-12 animals / condition. Fold increase in NIR average radiance efficiency of (F) wild-type and (G) MJD transgenic animals, n=4-6 animals / condition. Data are presented as mean ± SEM, two-way ANOVA with Dunnett's multiple comparisons test; statistical significance for Lipo-ICG DAS: *p < 0.05, **p < 0.01, ***p < 0.001; statistical significance for Lipo-ICG IKRG:#p < 0.05,###p < 0.001; statistical significance for Lipo-ICG NT:&p < 0.05.(H) Ex vivo fluorimetry quantification of ICG signal in MJD transgenic mice brain and peripheral organs (liver, spleen, heart, lungs, and kidney) lh after liposomes injection. ICG fluorescence intensity for each condition and each organ is normalized to the baseline signal obtained for each organ of non-injected animals (red line). Data are presented as mean ± SEM, unpaired t-test with Welch's correction; *p < 0.05; n=3 animals / condition.
[0094] Figure 9: Survival and differentiation of GFP-expressing murine NSC after transplantation into MJD transgenic mice treated with free SAG, Lipo-DAS SAG, or Lipo-NT SAG. (A-O) Representative immunofluorescence confocal microscopy images of neuronal marker NeuN (red) and astroglial marker SOX9 (purple) in animals treated with (A-E) 30 mg / kg SAG, (F-J) Lipo-DAS SAG, or (K-O) Lipo-NT SAG every other day starting 7 days after cell transplantation. Images show that six weeks after cell transplantation, SAG, Lipo-DAS SAG, or Lipo-NT SAG treated mNSC grafts have SOX9-positive glial cells and NeuN-positive neurons illustrated by the colocalization between GFP and SOX9 or NeuN, respectively. (P) Summary table of the identification of surviving transplant, percentage of GFP-expressing mNSC differentiated into mature neurons (NeuN+) and mature astrocytes (SOX9+) in the different conditions tested. DAPI: blue. SAG 30 mg / kg n=l, Lipo-DAS SAG n=3, Lipo-NT SAG n=2 mice. Scale bars: 50 pm.DETAILED DESCRIPTION
[0096] The present disclosure relates to a liposomal composition comprising a plurality of pH-sensitive liposomes, each liposome comprising: an outer lipidic shell, an aqueous inner core, and at least one molecule bound to the outer lipidic shell; wherein the aqueous inner core incorporates at least onetherapeutic molecule by encapsulation, adsorption or complexation. The present disclosure further related to the method for obtaining said liposomal composition and uses thereof.
[0097] The present disclosure relates to PEGylated, pH-sensitive, and brain-targeted liposomal compositions configured for the delivery of therapeutic agents across the blood-brain barrier, particularly for the treatment of neurodegenerative disorders. The liposomes comprise a phospholipid layer including pH-responsive lipids and at least one brain-targeting ligand attached to the liposomal surface, enabling selective accumulation within brain tissue and controlled release of the encapsulated payload under acidic conditions. The compositions may encapsulate a wide range of therapeutic agents, including smoothened agonist (SAG), small molecules, nucleic acids, peptides, proteins, and biologies.
[0098] Unexpectedly, the disclosed liposomal compositions encapsulating SAG demonstrated the ability to enhance neuronal differentiation of human neuroepithelial stem cells (hNESCs) in vitro, as evidenced by an increased number of NeuN-positive mature neurons. In vivo studies further demonstrated efficient brain targeting, with liposomes functionalized with the DAS peptide (SEQ ID NO: 1) and the IKRG peptide (SEQ ID NO: 2) achieving brain accumulation levels of approximately 22% and 29%, respectively, in murine models. Additionally, reduced accumulation in peripheral organs was observed for the targeted liposomes relative to non-targeted formulations, indicating improved biodistribution and targeting specificity.
[0099] Moreover, DAS-targeted liposomes encapsulating SAG promoted the survival of transplanted murine neural stem cells (mNSCs) in Machado-Joseph disease (MJD) transgenic mice and enhanced differentiation of the transplanted cells into NeuN-positive mature neurons six weeks after transplantation. These results demonstrate the potential of the disclosed liposomal platform to improve targeted delivery to the central nervous system, enhance neuronal differentiation and regeneration, and provide therapeutic benefits in neurodegenerative and neurological disorders.
[0100] In the context of the present disclosure, four promising drugs, Folic Acid, Salbutamol, Smoothened Agonist, and Ibuprofen were selected for their potential to enhance neural stem cell differentiation. Taking into consideration that some of these molecules are potent drugs, one efficient way to reduce toxic side effects and the undesired activation of stem cells niches outside the brain (possibly leading to tumor formation) is their encapsulation in drug delivery vehicles, preferably liposomes, which can increase their preferential delivery to the brain, while improving their safety in circulation.
[0101] In the context of the present disclosure, stealth, pH-sensitive, and brain-targeted liposomes encapsulating Smoothened Agonist (SAG) were developed. Liposomes were composed by 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),Cholesterol, and l,2-Dioctadecanoyl-sn-glycero-3-phosphoethanolamine (DSPE)-Hydrazone-PEG2000. Brain-targeting ligands DAS (SEQ. ID NO 1), IKRG (SEQ. ID NO 2), and RVG-9r (SEQ. ID NO 3) were added by post-insertion method, using DSPE-PEG-Maleimide micelles conjugated to the targeting ligand. Finally, the developed brain-targeted liposomes were characterized for their drug encapsulation efficiency, ligand post-insertion yield, size, polydispersity index (PDI), zeta potential, pH sensitivity, and for their biodistribution and ability to enhance neural differentiation in vitro and in vivo.
[0102] Transplantation of neural stem cells such as hNESC, holds the promise to rehabilitate the lost brain tissue in neurodegenerative diseases, and improve the overall brain microenvironment by reduction of neuroinflammation and production of neurotrophic factors. Nonetheless, the reduced brain plasticity commonly encountered in aged brains as a result of impaired neurotrophic factors, may be hindering the potential of stem cell therapies to achieve further success in treating neurodegenerative diseases. In the context of the present disclosure, cellular and molecular pathways that are altered during neurodevelopment and throughout aging were identified. Then, small-molecule drugs, reported to modulate the identified pathways, were tested for their potential to induce hNESC differentiation in vitro. One of these was further selected to be encapsulated in PEGylated, pH-sensitive, and brain-targeted liposomes and tested in vitro and in vivo. The small-molecule drugs selected were Ibuprofen, Folic Acid, Salbutamol, and Smoothened Agonist.
[0103] Ibuprofen is nonsteroidal anti-inflammatory drug widely used in clinical practice for its analgesic and antipyretic effects. Ibuprofen's molecular mechanisms centers on the inhibition of cyclooxygenase (COX-1 and COX-2), which are responsible for the production of prostaglandins, lipid molecules with a role in inflammation, pain, and fever. Over the last few years, the use of Ibuprofen to enhance neural stem cells differentiation has been explored. For example, Wallenquist and colleagues combined transplantation of murine neural stem cells with Ibuprofen treatment in a mouse model of traumatic brain injury. Beside reduction in neuroinflammation after treatment with Ibuprofen, the authors also reported increased differentiation. The use of Ibuprofen in a transgenic mouse model of MJD, a significant reduction in mRNA levels of neuroinflammatory markers ( / / .-ip and TNFa), increased number of neural progenitor cells in the subventricular zone, preserved neuronal tissue, cerebellar atrophy reduction, as well as mutant Ataxin-3 inclusions reduction, and, motor performance improvement were observed. The exact mechanism by which Ibuprofen induces neural stem cells differentiation is still yet not fully understood. Nonetheless, some work has hinted potential molecular mechanisms involved. One such mechanisms is the alteration of the prostaglandin levels, like PGE2, which has been demonstrated to influence neural stem cells differentiation. Another potential pathway might be the activation of peroxisome proliferator-activated (PPA) receptors, especially PPAR-a, which have been shown to enhance neurogenesis. Moreover, Ibuprofen, by reducing neuroinflammation, can modulatethe brain microenvironment to create more permissive conditions for neural stem cells differentiation. In the context of the present disclosure, differentiation by Ibuprofen was observed by the increase in the MAP2 and TUBBS mRNA expression, (Figure II), as well as by the increase in P3-tubulin and MAP2 staining observed by immunocytochemistry (Figure 2E-H).
[0104] Folic acid, also known as vitamin B9, is a small compound with recognized functions in DNA synthesis, repair, and methylation. Folic Acid has also shown to impact neural differentiation in vitro. Luo and colleagues found that supplementation of the culture media of rat primary neural stem cells for 6 days with 8 and 32 pg / mL of Folic Acid led to a significant increase in the number of P3-tubulin positive neurons. Similarly, a significant increase in the mRNA levels of TUBBS was found in the context of the present disclosure after 6 days incubation of hNESC with 100 pM Folic Acid (Figure IL). At a molecular level, Folic Acid is able to play a role in neural differentiation by regulating the expression of transcription factors in pathways such as NOTCH, Sonic Hedgehog, and WNT signaling pathways. In the context of the present disclosure, a significant reduction of mRNA levels of NOTCH1 after incubation with 100 pM Folic Acid (Figure IL) was observed. This is in accordance with a work that demonstrated that increased activation of the NOTCH signaling pathway is important in the proliferation of neural stem cells and their maintenance in an undifferentiated state.
[0105] Salbutamol is a commercially available drug (also known as albuterol) commonly used as a bronchodilator to treat symptoms of asthma and chronic obstructive pulmonary disease. It works through the activation of P2 adrenergic receptors, which are mainly expressed in the lungs but in the CNS as well. Although the evidence for direct effect of Salbutamol in neural differentiation is still to be established, strong evidence exists for the role of P2 adrenergic receptors activation in neurogenesis. Additionally, one recent work on FDA-approved drug repurposing found that Salbutamol significantly increased in vitro and in vivo the levels of FGF20, a growth factor important in neuronal support and maintenance. To the present date, no study has tested this drug with the purpose to enhance stem cell differentiation. In the context of the present disclosure, the results show only an increase in TUBBS and MAP2 mRNA levels with high variability, and no direct influence on the mRNA levels of FGF20 (Figure IK).
[0106] Smoothened agonists are a class of small molecule compounds that act on the G-protein coupled receptor Smoothened (SMO) involved in the Sonic Hedgehog (SHH) pathway. In physiological conditions, SHH binds to its receptor Patched (PTCH), removing the inhibition on SMO, and allowing the downstream activation of SHH pathways, including the expression of glioma associated oncogenes (GLI) transcription factors. The SHH pathway is crucial in the regulation of cell growth, differentiation, and development. The activation of the SHH pathway using Smoothened Agonist has been related to increased survival, proliferation, and differentiation of neural stem cells in vitro and in vivo, andremyelination and regeneration after injury. Enhanced differentiation, namely into oligodendrocytes progenitor cells, has been associated with reduced levels in GLI1. This is in accordance with the increase in mRNA levels of MAP2 and TUBBS, and significant increase in the protein levels of MAP2, P3-tubulin, and GFAP observed, while finding a significant decrease in mRNA levels of GLI1 and a decrease for GLI1 protein levels, after hNESC 6 days incubation with SAG (Figure 1J and Figure 2Q-V).
[0107] Moreover, using the same Smoothened Agonist, Maury et al. and Xu et al., were able to induce differentiation of human iPSC and murine ESC, respectively, into mature and functional motor neurons. In vivo, the administration of SAG has been demonstrated to enhance the survival of newly generated neural cells in the dentate gyrus after intracerebroventricular administration, promoting neurogenesis. In the context of the present disclosure, SAG ability to enhance neural differentiation in vivo in hNESC transplanted into NOD.SCID mice was assessed after 3 i.p. administrations every other day 7 days after surgery and animals sacrificed 6 weeks post-transplantation. Indeed, co-localization of MAP2 and GFAP was detected in GFP-expressing hNESC (Figure 3), indicating that these cells differentiated in vivo, similarly to what was observed by us previously. More interestingly, the quantification of mature NeuN-positive cells co-localized with the GFP-expressing graft, demonstrated a significant increase (20.8%) of the percentage of NeuN-positive cells in animals treated with SAG 30 mg / kg, comparing to non-treated controls (0.7%) (Figure 4). Together, these results indicate that SAG promotes human iPSC-derived hNESC differentiation in vitro and in vivo.
[0108] As so, SAG was the differentiation-inducing drug most promising to be encapsulated in the liposomes for a targeted delivery in transplanted neural stem cells. SAG is a potent drug, used in the nanomolar scale, and its potential side effects are not yet fully known. Nonetheless, the activation of the SHH pathway has been shown to activate neurogenesis, by enhancing neural stem cells survival and differentiation, without any reported adverse side effects, but is also associated with carcinogenesis. Thus, SAG encapsulation in liposomes can specifically direct their cargo to target cells, potentially improve the drugs' biodistribution and allow the reduction of the administered dose and accumulation in peripheral organs, reducing undesired side effects. The work of the present disclosure provides for the first time the encapsulation of SAG into liposomes to enhance the differentiation of neural stem cells after transplantation into mice's cerebellum.
[0109] The application of liposomes to treat neurodegenerative diseases is becoming more frequent and with encouraging results. Some authors have been exploring the use of retinoids encapsulated in liposomes to induce the differentiation of neuroblastoma cells in vivo and in vitro. Others have been testing the activation of the neurogenic niches in the brain using liposomes as delivery vehicles for several different types of molecules. However, the use of stealth, pH-sensitive, and brain-targetedliposomes to deliver differentiation-inducing small-molecule drugs in co-therapy with stem cells transplantation, as disclosed herein, is not found yet in the state of the art.
[0110] Each component of the liposomes of the present disclosure was carefully selected to produce a stable, stealth and pH-sensitive liposomes, able to encapsulate SAG and with a targeting ligand to direct the particles to the brain. The liposomes of the present disclosure have a size around 130 nm and PDI lower than 0.3 (Table 2), which are considered standard characteristics to achieve stable, long circulating liposomes. Furthermore, with a surface charge of around -10 mV (Table 2), the liposomes are considered slightly negative. A slightly negative surface charge is advised in order to repel opsonins, additionally increasing circulation times, and is associated with enhanced liposomes stability in vivo. SAG encapsulation through pH gradient was above 80% for all the developed formulations (Table 2), which is in accordance with what is described in the literature for drug encapsulation efficiencies using pH gradient method, usually with very high encapsulation efficiencies. Furthermore, the pH-sensitivity at weakly acidic environments, such as endosomes, conferred to the formulation by the addition of the hydrazone bound is very well studied, with reports showing up to 80% release of cargo at pH 4.5 for 3h. In the context of the present disclosure, after just 10 min incubation at pH 5.5, a 46% increase in rhodamine B signal compared to incubation at physiological pH was observed (Figure 5N), revealing that the liposomes of the present disclosure become rapidly unstable in the presence of weakly acidic environments.
[0111] Off -target effects are a major concern in therapies aimed to be administered in a systemic and minimally invasive way. Beside the protection of the cargo molecules and an enhancement of the circulation times of these molecules by incorporation in liposomes, these nanoparticles can also be tailored to present on their surface targeting ligands that can preferentially direct the therapies to specific organs and cells, reducing the off-target effects. Hence, brain targeting ligands IKRG (SEQ. ID NO 2) and DAS (SEQ. ID NO 1) were tested for their ability to be internalized in vitro and coupled by the post-insertion method to the liposomes. IKRG (SEQ. ID NO 2) is a peptide, analogue to BDNF, used as targeting ligand in PEG-PCL (polyethylene glycol-polycaprolactone) polymeric nanoparticles designed to target the TrkB receptor in neurons. Interestingly, some of the differentiation inducing effects observed by using the IKRG-targeted formulation may be due to the fact that the activation of TrkB receptor by a molecule analogue to BDNF can influence this molecular pathway, leading to neural differentiation. DAS (SEQ. ID NO 1) is peptide derived from RDP with improved serum stability and optimized interaction with the a7 subunit of the nicotinic acetylcholine receptor, shown to enhance neuroblastoma cells targeting and increased ability to cross the BBB in an in vitro model. The present disclosure provides, for the first time, IKRG (SEQ. ID NO 2) and / or DAS (SEQ. ID NO 1) as targeting ligands in liposomes.
[0112] In the context of the present disclosure, IKRG (SEQ. ID NO 2) demonstrated increased ability to target hNESC in the in vitro model of BBB, demonstrating that this targeting ligand is also able to transpose the BBB (Figure 5M). DAS (SEQ. ID NO 1) presented significant increased internalization in all the in vitro models tested, namely incubation with hNESC, hNESC-differentiated neural cultures, and the in vitro BBB model (Figure 5M). These results indicate the ligand's ability to target neurons and successfully overcome in vitro BBB models as previously reported. Both ligands were successfully inserted in the liposomes, although with different efficiencies due to different times and temperatures used in the post-insertion method. The post-insertion efficiency for IKRG (SEQ. ID NO 2) was 33.3 ± 18.7%, while for DAS (SEQ. ID NO 1) it was 13.8 ± 10.8% (Table X). Usually, at high temperatures above the transition temperature of the lipids that make the liposomes (65°C in the context of the present disclosure), post-insertion efficiencies are increased compared to lower temperatures; this was the case for IKRG post-insertion. For DAS (SEQ. ID NO 1), the post-insertion had to be performed at 39°C overnight because DAS (SEQ. ID NO 1) aggregated at 65°C. At 39°C, the liposomes membrane is more rigid, since this is below the phase transition temperature of the lipids (55°C), hampering the molecular substitution of lipids for targeted micelles.
[0113] Furthermore, cellular uptake of targeted and non-targeted liposomes encapsulating rhodamine B by hNESC was evaluated by flow cytometry and confocal microscopy, after 4h incubation at 37°C or 4°C (Figure 6). As expected, DAS-targeted liposomes cell internalization was enhanced at 37°C compared with 4°C. On the other hand, no difference in non-targeted liposomes uptake was detected between 4°C and 37°C internalization (Figure 6E-H), indicating that these liposomes are internalized in a ATP-independent manner, independently of energy requirements, namely by electrostatic interactions between the lipids in the liposomes and the cell membrane.
[0114] In the context of the present disclosure, the brain delivery capacity and the accumulation in peripheral organs of liposomes encapsulating ICG and targeted with IKRG (SEQ. ID NO 2), DAS (SEQ. ID NO 1), or non-targeted was evaluated (Figure 8). A statistically significant increase in ICG signal detected using the I VIS Lumina equipment was observed for the formulation targeted with IKRG (SEQ. ID NO 2) in wild-type animals at the time points of 3h and 6h (Figure 8E-F). This data indicates that IKRG-targeted liposomes remain in circulation for increased time points, while preferentially accumulate in the brain after 3h. This difference may be caused by a higher difficulty of these liposomes to transpose the BBB, since IKRG (SEQ. ID NO 2) is a ligand that specifically targets TrkB, a receptor much more expressed in neurons than endothelial cells of the BBB. Moreover, the difference observed in the brain accumulation of IKRG-targeted liposomes in wild-type mice and MJD-transgenic mice, despite the later animals presenting a compromised BBB that facilitates the entry of the liposomes in the brain, hints that the TrkB receptor can be altered in these animals, causing this difference in brain accumulation. Furtherexperiments are required to evaluate whether this hypothesis is correct. DAS-targeted liposomes presented significant increase in brain accumulation in the earlier time points, until de 3h mark, and steadily decreased during all time points evaluated (Figure 8E-G). Brain accumulation of DAS-targeted liposomes was particularly increased in MJD-transgenic animals (Figure 8G), due to the compromised BBB that these animals present. Moreover, in all peripheral organs the ICG signal of IKRG- and DAS-targeted liposomes was decreased compared to non-targeted liposomes, especially in the liver, the major organ responsible for the accumulation and elimination of foreign bodies, where non-targeted liposomes presented a 35% increase accumulation (Figure 8H). This data indicates that targeted liposomes accumulate less in peripheral organs than non-targeted liposomes, causing fewer undesired side effects and being safer to use in a therapeutic context. Additionally, the present disclosure presents several advantages for clinical translation. Namely, the systemic administration of SAG encapsulated in liposomes is much safer and minimally invasive than direct cranial injection and associated with a lower dose administration, reducing potential secondary effects and accumulation in peripheral organs.Finally, the encapsulation of SAG into liposomes resulted in more animals presenting GFP-expressing graft, namely, the Lipo-DAS SAG treated group showed 3 animals in 5 with graft, the Lipo-NT SAG treated group 2 animals in 5, and the i.p. administration of SAG group 1 animal in 5 (Figure 9).Furthermore, despite the reduced number of transplanted cells identified, mature neurons (NeuN+) and astrocytes (SOX9+) in the grafted GFP-expressing mNSC were quantified (Figure 9A-O). Interestingly, the percentage of NeuN+ cells was 90.3% in animals treated with Lipo-DAS SAG, while Lipo-NT SAG treated animals had 70.3% of NeuN+ cells (Figure 9P). This result indicates that the delivery of SAG through brain-targeted liposomes is able to further enhance the differentiation of the transplanted mNSC in vivo. Nonetheless, the reduced survival of mNSC in MJD-transgenic mice needs to be overcome in future studies to confirm the potential of DAS-targeted liposomes to deliver SAG and improve the differentiation of the transplanted cells. Moreover, the success of cell replacement strategies is often assessed by functional recovery in disease models. However, MJD lacks an immunocompromised mouse model that would not only confirm the liposomes potential to enhance neural stem cells differentiation in a cell model that could be used in the clinic but also assess the impact of this therapy in MJD neuropathology. Tacrolimus is an immunosuppressant commonly used in transplantation to avoid immune rejection. Nevertheless, this drug presents a narrow therapeutic window and is susceptible to drug interactions. These interactions can cause toxicity and reduced efficacy, namely given the described crosstalk between the immune system and stem cells, the use of immunosuppressants might hinder potential results in neural stem cells differentiation. Taken together, the present disclosure highlights the potential of SAG delivery through stealth, pH-sensitive, and brain-targeted liposomes to enhance neural stem cells differentiation in co-treatment with transplantation of neural stem cells.Assessment of drugs potential to induce hNESC neural differentiation in vitro and in vivo
[0115] The expression of genes related to neurogenesis altered during cerebellar neurodevelopment and throughout aging was assessed in BrainSpan atlas (atlas of the developing human brain, from Allen Institute for Brain Science; brainspan.org). After identifying these pathways, an extensive literature review searching for small-molecule drugs to modulate such pathways was performed and concentrations described to downregulate or upregulate their targets were selected. As so, Ibuprofen, a known COX-2 inhibitor that has demonstrated to induce neural differentiation, at the concentrations of 1 mM, 500 pM, 50 pM, and 5 pM; Smoothened Agonist, a modulator of the Sonic Hedgehog pathway, at the concentrations of 50 nM, 5 nM, 1 nM, and 0.5 nM; Salbutamol, an agonist of FGF20, at the concentrations of 100 pM, 50 pM, 5 pM, and 0.5 pM; and Folic Acid, a modulator of the NOTCH1 signaling pathway, at the concentrations of 100 pM, 10 pM, 1 pM, and 0.1 pM were selected to be tested as potential hNESC differentiation-inducing drugs in the context of the present disclosure.
[0116] The toxicity of the drug concentrations selected was tested in human iPSC-derived Neuroepithelial Stem Cells (hNESC). For this, hNESC viability was evaluated after 6-days drug incubation by resazurin reduction assay and fluorescein diacetate assay (Figure 1A-H). No major reduction in cell viability for most drugs and concentrations tested was observed; neither with the DMSO or ethanol concentration used (data not shown). However, Ibuprofen revealed significant reduction of cell viability of 80.77% in the resazurin reduction assay and 99.92% in FDA assay with highest concentration (Figure 1A-B); thus, this concentration was eliminated from further testing. For the concentration of 500 pM Ibuprofen, a significant reduction in cell viability of 30.44% in the resazurin reduction assay, and 55.49% in the FDA assay was observed (Figure 1A-B). Moreover, 0.5 pM Smoothened Agonist and 100 pM Folic Acid also promoted a significant cell viability reduction in the resazurin reduction assay that was not corroborated by the FDA assay. For most of the drugs and concentrations tested, the results obtained using resazurin reduction and fluorescein diacetate assays are similar in terms of each drug concentration triggers significant cytotoxicity, confirming their robustness. However, beside the effect of the drugs on cell viability these data might also indicate differences in metabolic rate observed in differentiated neural cultures compared to neural progenitor cells. Overall, taking into consideration both cell viability tests, excluding 1 mM and 500 pM Ibuprofen, no signs of significant cell viability reduction were detected in hNESC after incubation with Smoothened Agonist, Salbutamol, and Folic Acid for the concentrations tested.
[0117] Then the drugs were tested for their ability to modulate the expression of neuronal differentiation-related genes (MAP2 and TUBBS), as well as genes of their molecular targets (Figure II-L). For Ibuprofen, a 47.25% increase in the mRNA levels of MAP2 and 49.42% increase in the mRNA levels of TUBBS, at the concentrations of 500 pM and 50 pM, respectively, was observed. A significant60.55% reduction of the mRNA levels of PTGS2 was found, demonstrating the successful downregulation of the mRNA of the molecular target of Ibuprofen at the concentration of 500 pM (Figure 4.11). Regarding Smoothened Agonist, an increase of 61.15% in the MAP2 mRNA levels with 50 nM, and an increase of 115.61% and 146.10% in the TUBB3 mRNA levels with 50 nM and 5 nM, respectively, was found, indicating that SAG enhances hNESC differentiation. A significant reduction of 19.67% in the mRNA levels of GUI, using 5 nM SAG (Figure 1J) was observed. Regarding Salbutamol, an increase of 147.51% and 63.91% for the MAP2 mRNA levels at 50 pM and 0.5 pM, respectively, an increase of 170.79%, 111.21%, and 49.73% in TUBB3 mRNA levels at 50 pM, 5 pM and 0.5 pM, respectively, and no alteration of the mRNA levels of FGF20 were observed (Figure IK), revealing that Salbutamol may increase hNESC differentiation but the results are highly variable and the cell differentiation does not affect FGF20 mRNA levels. For Folic Acid, a significant increase of 54.77% in the TUBBS mRNA levels at 100 pM was observed (Figure IL), indicating that Folic Acid can potentiate early differentiation in hNESC. Moreover, a significant 33.71% reduction in the NOTCH1 mRNA levels after 6-days incubation with 100 pM Folic Acid was found (Figure IL). This data demonstrates that the selected drugs are safely used for hNESC differentiation modulation, although for most of the tested concentrations no significant changes were observed in the mRNA levels.
[0118] From the tested drugs, SAG was the most promising because TUBBS and MAP2 mRNA levels were closer to achieve a statistically significant increase and modulate the expression of its molecular target mRNA levels. Afterwards, the concentration that hinted the most promising results in the evaluation of the mRNA levels of differentiation-related genes, namely, 500 pM Ibuprofen, 50 nM Smoothened Agonist, 100 pM Folic Acid, and 50 pM Salbutamol, were selected to further test the potential differentiation of hNESC into neurons. Thus, hNESC were incubated with these drug concentrations for 6 days and neuronal differentiation evaluated by immunocytochemistry (Figure 2A-T). Increased neuronal markers P3-tubulin (red)- and MAP2 (white)-positive cells presenting neuron-like morphology and network organization were more robustly detected in cell cultures after incubation with 500 pM Ibuprofen (Figure 4.2E-H), and 50 nM Smoothened Agonist (Figure 2Q-T). While no clear and robust difference was detected between CNT and drug-treated hNESC regarding differentiation into GFAP-positive astrocytes (Figures 2.C, 2G, 2K, 20, 2S). Altogether, SAG promoted increased mRNA expression levels of MAP2 and TUBBS compared to the other drugs. Moreover, the use of SAG to enhance hNESC differentiation is widely unexplored, presenting more innovative potential than the use of Ibuprofen.
[0119] Consequently, 50 nM Smoothened Agonist was selected to evaluate the protein levels of neural differentiation-related proteins (MAP2, P3-tubulin, and GFAP) after 6-days incubation with hNESC compared to non-treated hNESC controls by Western-Blot (Figure 2U-V). Data revealed a significantincrease of 87.52% and 100.05% in the protein levels of MAP2 and P3-tubulin, respectively, and a significant increase of 29.78% in the protein levels of GFAP after 6-days incubation with 50 nM SAG (Figure 2V). Altogether, the mRNA and protein expression indicate that the incubation of hNESC with 50 nM SAG promotes hNESC differentiation in vitro.
[0120] To evaluate if SAG presents similar differentiation-inducing potential in vivo, NOD.SCID mice were transplanted with GFP-expressing hNESC (green) and treated with 3 intraperitoneal injections of SAG 30 mg / kg every other day, starting 7 days after surgery. No further treatment after cell transplantation (control, Figure 3 and 4) was done to control animals. Six weeks after cell transplantation, grafts were analyzed for the presence of mature neural cells. In either condition, very good graft survival was observed (Figure 3A-B) with human grafts presenting strong GFP expression and neuronal projections. Furthermore, the expression of MAP2 (red) and GFAP (purple) was detected colocalized with GFP-expressing hNESC (green), shown by the yellow and white cells, respectively, and observed both in control and SAG-treated animals (Figure 3C-J). The expression of mature nuclear neuronal (NeuN) and astrocytes (SOX9) markers was also observed co-localized with the transplanted GFP-expressing hNESC in both control and SAG treated animals (Figure 4A-P). Additionally, after quantification of SOX9 co-localization with the transplanted GFP-expressing hNESC, a 2.5-fold increase in the number of SOX9-positive astrocytes (6.46%) in animals treated with SAG 30 mg / kg was found compared to non-treated controls (2.91%) (Figure 4Q). Interestingly, in animals treated with SAG 30 mg / kg, a significant increase (20.77%) of NeuN-positive neurons was detected compared to non-treated control mice (0.68%) (Figure 4R). Thus, these data demonstrated that the administration of 30 mg / kg SAG in vivo can enhance hNESC differentiation after transplantation into NOD.SCID mice.
[0121] Subsequently, given the promising results obtained by SAG in vitro and in vivo regarding the potentiation of hNESC differentiation, and the innovative nature of the use of this drug in brain-targeted liposomes to enhance the differentiation of stem cells after cerebellar transplantation, SAG was further selected for encapsulation into liposomes and further testing in vitro and in vivo. Furthermore, the encapsulation of SAG into stealth, pH-sensitive, and brain-targeted liposomes improves the drugs' biodistribution, promoting its accumulation in the brain, protect SAG from metabolization and elimination, and allow a specific SAG release in the target cells reducing side effects and improving SAG safety profile.Development of stealth, pH-sensitive brain-targeted liposomes encapsulating SAG
[0122] After the testing and selection of the hNESC differentiation-inducing drug, the work of the present disclosure focused on the development of PEGylated, pH-sensitive, and brain-targeted liposomes, able to encapsulate Smoothened Agonist and assess the delivery to hNESC.
[0123] Firstly, an extensive literature review of targeting ligands used to direct nanoparticles into the brain and to specific sub-types of brain cells was carried out. Based on this revision, 3 targeting ligands were selected to be tested in vitro, namely, DAS (SEQ. ID NO 1), IKRG (SEQ. ID NO 2), and RVG-r9. DAS (SEQ. ID NO 1) is an optimized neural cell-targeting peptide, with improved serum stability and docking ability, based in the rabies virus-derived peptide, which targets the neural a7 subunit of the nicotinic acetylcholine receptor. IKRG (SEQ. ID NO 2) is a short peptide sequence that was reported to mimic the function of BDNF and targets TrkB receptors, widely expressed in neurons. RVG-r9 is a short peptide derived from the rabies virus glycoprotein, with 9 arginines coupled to enhance cell internalization, and already used as a targeting ligand for liposomes with promising results.
[0124] After the selection, ligands conjugated with the fluorescent FITC probe were tested for their ability to be internalized by hNESC, hNESC-derived neural cultures, or hNESC plated in an in vitro BBB model. Through confocal imaging, the cells treated with the selected ligands at the concentration of 20 pg / mL, especially DAS (SEQ. ID NO 1) and RVG-r9, presented a strong fluorescence signal after 4-hour incubation, for both hNESC and hNESC-derived neural cultures, (Figure 5A-L). The FITC-signal quantification revealed a significant increase of 11851.90 RFU (relative fluorescence units) and 14901.80 RFU in fluorescence intensity measured in hNESC after the incubation with DAS (SEQ. ID NO 1) and RVG-r9, respectively, compared to cells incubated with free FITC (3.48 RFU) (Figure 5M). A significant fluorescence intensity of 12466.60 RFU and 12631.40 RFU was also detected in hNESC-derived neural cultures after incubation with DAS (SEQ. ID NO 1) and RVG-r9, respectively, compared to cells incubated with free FITC (53.52 RFU) (Figure 5M). Interestingly, incubation with IKRG-FITC triggered no significant increase in fluorescence intensity in hNESC and hNESC-derived neural cultures, but in the in vitro BBB model IKRG presented a significant increase of 103.88 RFU compared to free FITC (1.00 RFU). DAS (SEQ. ID NO 1) also demonstrated a significant increase of 104.90 RFU compared to free FITC in the in vitro BBB model. On contrary, RVG-r9 showed no significant increase in fluorescence signal the in vitro BBB model (Figure 5M). Thus, DAS (SEQ. ID NO 1) and IKRG (SEQ. ID NO 2) were selected to be used as targeting ligands in the formulated liposomes, since they presented greater potential to overcome the BBB in the in vitro BBB model compared to RVG-r9. Additionally, RVG-r9 had already been used as a brain-targeting ligand in liposomes. Hence, the use of DAS (SEQ. ID NO 1) and IKRG (SEQ. ID NO 2) to brain-target liposomes holds substantial innovative potential.
[0125] The novel developed liposomes were composed of DOPE:DSPC:CHOL:DSPE-Hz-PEG2000 at the molar ratios of 37:22:33:8, prepared using the thin-film hydration method. Each of these lipids serves a specific purpose in the formulation and is crucial for liposomes structural integrity, physicochemical properties, and biological function. DOPE (l,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine, CAS Number: 4004-05-1) is a non-bilayer forming lipid crucial for membrane fusion, which increasesliposome permeability and enhances liposomes' ability to release the encapsulated cargo into the cell. DSPC (Distearoylphosphatidylcholine, CAS Number: 816-94-4) is a bilayer-forming saturated phospholipid important for structure and stability, creating a rigid and stable membrane, and presents a high transition temperature, enabling structural integrity in circulation and preventing premature leakage. Also, cholesterol, CAS Number: 57-88-5, is essential in maintaining liposomes' stability by preventing excessive membrane fluidity and influencing their size. DSPE-Hz-PEG2000 (1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Hydrazone] Polyethylene Glycol 2000) is an important component in the liposome formulation of the present disclosure. PEGylation is fundamental in creating stealth liposomes, to achieve effective drug delivery in vivo and prevents liposomes aggregation, contributing to formulation stability. The hydrazone (Hz) linker in this lipid provides pH sensitivity, enabling the cleavage of PEG in acidic conditions, such as inside the endosome after internalization, enhancing liposomes destabilization. SAG was encapsulated using the pH-gradient method. To optimize the pH gradient for SAG encapsulation, pH 10.5 was used in the aqueous core of the liposomes, and for the external solution, 3 different pH were tested (10, 11, and 12). The pH gradient took into consideration the pKa of SAG, which is 10.64 ± 0.40 (as described by the manufacturer), and pH of 10, 11, and 12 for external buffer were tested to promote SAG protonation and encapsulation in the liposomes. The obtained results revealed that only for pH 11 SAG encapsulation was consistently detected (Table 1). Ligands were added to the liposomes through the post-insertion method using DSPE-PEG-Maleimide micelles conjugated with targeting ligand by reaction between a thiol in the ligand and maleimide in micelles. Table 1. pH tested to optimize SAG encapsulation by the pH gradient method; pH 10 n=3; pH 11 n=4; pH 12 n=4.External pH Internal pH Final SAG concentration10 10.5 Not detected11 10.5 18.95 pM12 10.5 Not detected
[0126] Hence, 3 types of liposomes were formulated encapsulating SAG or rhodamine B for testing in vitro: (i) Liposomes with DAS (SEQ. ID NO 1) as targeting ligand (Lipo-DAS), (ii) Liposomes with IKRG (SEQ. ID NO 2) as targeting ligand (Lipo-IKRG), and (iii) Liposomes without targeting ligand (Lipo-NT).
[0127] Table 2 depicts the composition of the 3 types of liposomes formulated encapsulating SAG or rhodamine B: Lipo-DAS, Lipo-IKRG and Lipo-NT.Table 2. Composition of the 3 types of liposomes formulated encapsulating SAG or rhodamine B (Lipo- DAS, Lipo-IKRG and Lipo-NT) of the present disclosure; DOPE: l,2-Dioleoyl-sn-Glycero-3- Phosphoethanolamine; DSPC: distearoylphosphatidylcholine; CHOL: cholesterol; DSPE-Hz-PEG2000: 1,2- Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Hydrazone] Polyethylene Glycol 2000; NT: nontargeted; SAG: smoothened agonist.Liposomes formulated ComponentLipo-DAS Lipo-IKRG Lipo-NT Chemical Entity CAS NumberDOPE (mol%) 4004-05-1 37 37 37 DSPC (mol%) 816-94-4 22 22 22 Core lipid compositionCHOL (mol%) 57-88-5 33 33 33 DSPE-Hz- PEG2000 - 8 8 8 (mol%)DAS (SEQ. ID NO 1) 4 - - Targeting ligand (mol%) IKRG (SEQ. ID NO 2) - 4 - NT - - - DAS-conjugated DSPE-PEG-Mal4 - - micellesPost-inserted surfaceIKRG-conjugated DSPE-PEG-Malcomponent (mol% - 4 - micellesrelative to total lipid)Not-targeted DSPE-PEG-Mal- - 4 micellesSAG: 1:16 (SAG: 1:16 (SAG: 1:16 SAG / total SAG / total SAG / total lipid molar lipid molar lipid molar SAG (mol%) or rhodamine B ratios or ratios) or ratios) or 10 mM of 10 mM of 10 mM of rhodamine rhodamine rhodamine B B B
[0128] The liposomes characteristics for each formulation developed in the context of the present disclosure are summarized in Table 3. The mean size of the liposomes was 126.5 ± 9.7 nm, 125.8 ± 9.6 nm, and 134.95 ± 4.2 nm for Lipo-DAS, Lipo-IKRG, and Lipo-NT, respectively, revealing a uniform size around 125-135 nm. Polydispersity index was 0.135 ± 0.09, 0.236 ± 0.05, and 0.16 ± 0.10 for Lipo-DAS, Lipo-IKRG, and Lipo-NT, respectively, demonstrating homogenous size distribution of the particles. Liposomes zeta potential was -9.18 ± 1.25 mV, -10.77 ± 2.04 mV, and -12,42 ± 3,15 mV for Lipo-DAS, Lipo-IKRG, and Lipo-NT, respectively, indicating slightly negative surface charge of the particles. All formulations presented high SAG encapsulation efficiency, 95.6 ± 1.8%, 86.1 ± 12.4%, and 82.5 ± 6.7% for Lipo-DAS, Lipo-IKRG, and Lipo-NT, respectively. The post-insertion efficiency of the targeting ligands was 13.8 ± 10.8% for Lipo-DAS, and 33.3 ± 18.7% for Lipo-IKRG. The difference of the yield between both ligands might be explained in part by the fact that their post-insertion must be done at different temperatures. IKRG (SEQ. ID NO 2) post-insertion was performed at 65°C, while DAS (SEQ. ID NO 1) aggregated at this temperature. So, DAS (SEQ. ID NO 1) post-insertion had to be done at 39°C, which results in a lower yield.
[0129] To evaluate the liposomes pH sensitivity, liposomes encapsulating rhodamine B were tested for RhB release according to a previously published method. Compared to physiological pH, at pH 5.5 liposomes present a significant increase of 46.00% in rhodamine B signal, demonstrating the pH- sensitivity of the formulated liposomes (Figure 5N). Also, the ability of targeted liposomes to be uptaken by hNESC and release their cargo in the cytoplasm was evaluated. For this, FITC-tagged IKRG-targeted liposomes loaded with rhodamine B were incubated with hNESC for 4 hours. By confocal microscopy, the cell uptake of the liposomes (green dots) and the presence of rhodamine B (red) inside hNESC (Figure 5O-T) compared to control (non-treated hNESC) was observed, revealing the ability of targeted liposomes to be internalized by hNESC and release their cargo in these cells; since rhodamine B was encapsulated at quenched concentration the emission of rhodamine B fluorescence (red) indicates its release from the liposomes inside the cells.Table 3. Summary of the characteristics of the formulations tested; Lipo-DAS: liposomes targeted with DAS (SEQ. ID NO 1); Lipo-IKRG: liposomes targeted with IKRG; Lipo-NT: liposomes non-targeted; nm: nanometers; PDI: polydispersity index; SAG: Smoothened Agonist; N.A.: not applicable.Zeta potential SAG encapsulation Post-insertion Formulation Size (nm) PDI(mV) efficiency (%) efficiency (%) 126.5 ± 0.135 ±Lipo-DAS -9.18 ± 1.25 95.6 ± 1.8 13.8 ± 10.89.7 0.09Lipo-IKRG 125.8 ± 0.236 ± -10.77 ± 2.04 86.1 ± 12.4 33.3 ± 18.7Zeta potential SAG encapsulation Post-insertion Formulation Size (nm) PDI(mV) efficiency (%) efficiency (%) 9.6 0.05134.95 ± 0.16 ±Lipo-NT -12.42 ± 3.15 82.5 ± 6.7 N.A.4.2 0.10
[0130] Furthermore, the ability of rhodamine B (RhB)-loaded targeted (with DAS or IKRG) or nontargeted liposomes to efficiently and actively deliver their cargo in hNESC was assessed. For this, 0.1 pmol of total lipid for each formulation was incubated with hNESC for 4 hours at 37°C or 4°C. At 4°C, energy-dependent mechanisms, such as receptor mediated internalization, are stopped. So, a decrease in rhodamine B signal was expected when targeted liposomes were incubated with the hNESC at 4°C. Non-treated hNESC were used as control for fluorescence baseline parameters. Using confocal microscopy (Figure 6A-P), no significant difference was observed in rhodamine B signal when hNESC were incubated with Lipo-NT RhB at 37°C or 4°C (Figure 6E-H); whereas when incubated with Lipo-DAS RhB, a difference in rhodamine B signal is observed between 37°C and 4°C (Figure 61-L). Additionally, flow cytometry was used to detect the percentage of positive cells for rhodamine B in the different conditions (Figure 6Q-R). At 37°C, all formulations, Lipo-DAS, Lipo-IKRG, and Lipo-NT, presented a percentage of rhodamine B-positive cells around 70%. However, a statistically significant difference when comparing the percentage of rhodamine B-positive cells incubated with Lipo-DAS RhB at 37°C (68.95%) and 4°C (17.90%) was observed. This difference in not observed when hNESC are incubated with Lipo-IKRG RhB (62.73% for 37°C and 31.63% for 4°C), or Lipo-NT RhB (74.65% for 37°C and 53.58% for 4°C) (Figure 6R).
[0131] These results reveals that the internalization of liposomes targeted with DAS (SEQ. ID NO 1) is an active process, requiring energy expenditure to occur, such as in a receptor-mediated internalization. On the other hand, non-targeted liposomes appear to be internalized in an energy independent fashion, since the difference between the internalization at 4°C and 37°C is not significant, and the red puncta observed at the surface of hNESC indicates that these liposomes were not specifically attached to the cells (possibly through electrostatic interactions between the lipids in the liposomes and the cell membrane) rather than cell internalization.Liposomes capacity to induce hNESC neural differentiation in vitro
[0132] Thereafter, liposomes' ability to enhance neural differentiation of hNESC in vitro was evaluated (Figure 7). In this regard, 50 nM of SAG encapsulated in liposomes was incubated with hNESC for 6 days (with 2 administrations) or 4 weeks (with 4 administrations, once weekly). Firstly, by immunocytochemistry the expression of neuronal markers P3-tubulin and MAP2, and glial marker GFAPwas evaluated after 6 days incubation. An increased expression of P3-tubulin (red) and MAP2 (white), and a neuronal-like morphology and network organization after incubation with DAS- and IKRG-targeted liposomes compared to control hNESC was observed (Figure 7A-L). Moreover, IKRG-targeted liposomes presented higher P3-tubulin (red) and GFAP (green) expression compared with DAS-targeted liposomes.
[0133] No differences in the mRNA levels of TUBB3 and MAP2 were observed in cells treated with DAS and IKRG-targeted liposomes encapsulating SAG (Figure 7M), but an increase of 24.74% and 25.40% in the protein levels of P3-tubulin and MAP2, respectively, was observed when hNESC were incubated with Lipo-DAS SAG or Lipo-IKRG SAG, respectively, for 6 days compared to non-treated hNESC (Figure 7N-O).Furthermore, after 4 weeks incubation, an increase of 64.50% in the mRNA levels of TUBBS in hNESC incubated with Lipo-IKRG SAG, and a significant 57.00% increase in mRNA levels of GLI1 in hNESC incubated with Lipo-DAS SAG was observed by RT-qPCR comparing to non-treated hNESC (Figure 7P). As for the protein levels of P3-tubulin, MAP2, and GLI1, no differences comparing the liposomes-treated hNESC to control non-treated cells were found (Figure 7Q-R).
[0134] After 4 weeks incubation of hNESC with Lipo-DAS SAG or Lipo-IKRG SAG (with 4 administrations, once weekly), immunocytochemistry was performed to evaluate the expression of the neuronal mature marker NeuN (Figure 7S-Y). Microscopy analysis revealed a higher fluorescence signal for NeuN (red) in cells incubated both with Lipo-DAS SAG and Lipo-IKRG SAG compared to control non-treated hNESC (Figure 7S-X). Quantification of the percentage of NeuN-positive cells demonstrated a significant increase (74.91%) and an increase (61.27%) after incubation with Lipo-DAS SAG and Lipo-IKRG, respectively, compared to control non-treated hNESC (30.61%) (Figure 7Y).Liposomes biodistribution in MJD transgenic and wild-type mice
[0135] Having demonstrated the capacity of DAS- and IKRG-targeted liposomes to promote hNESC neural differentiation in vitro, the liposomes of the present disclosure were studied to assess whether they are capable to specifically deliver their cargo to mouse brain after intravenous administration. Liposomes containing a near infrared (NIR) dye, indocyanine green (ICG), were formulated and their accumulation in the brain evaluated using the IVIS Lumina equipment after injection in mice's tail vein. NIR images were acquired 15min, 30min, lh, 3h, 6h and 24h after intravenous administration of Lipo-ICG DAS, Lipo-ICG IKRG, and non-targeted Lipo-ICG NT, and compared to the signal of non-injected animals for baseline (Figure 8A-G). In this experiment, MJD transgenic mice and their wild-type littermates were used to assess if the brain-targeted liposomes have different behavior in crossing the BBB of transgenic animals in which the BBB is impaired and the expression of targets is as well dysregulated. Furthermore, this formulation has the goal to be used to improve cell therapy in the context of neurodegenerative diseases, such as MJD.
[0136] Assessing the signal acquired for all animals tested (total animals: wild-type and MJD transgenic), Lipo-ICG DAS (red line) presents a significant 2-fold increase in the measured signal in almost all time-points analyzed (except at 24h), Lipo-ICG IKRG (blue line) has a significant 2-fold increase in signal at time-points 3h and 6h, while Lipo-ICG NT (green line) has no significant increase in signal at any time-point measured compared to non-injected controls (black line) (Figure 8E). Interestingly, if the animals in wild-type and MJD transgenic groups are separated, the former Lipo-ICG DAS (red line) loses the significant signal increase in this subset, presenting only increases at the time points of 3h and 6h (p=0.0755 and p=0.0777, respectively), while Lipo-ICG IKRG (blue line), presents a more robust significant increase at the time-points of 3h and 6h compared to non-injected controls (black line) (Figure 8F). Regarding MJD transgenic mice, Lipo-ICG DAS (red line) presents a robust significant increase in the measured signal at earlier time-points, specially 15 min, 30 min and lh, while Lipo-ICG IKRG (blue line) only presents an increase at the time points of 15 min and lh (p=0.0606 and p=0.0813, respectively) compared to non-injected controls (black line) (Figure 8G). In conclusion, in the context of MJD, DAS (SEQ. ID NO 1) is the best suited to promote brain accumulation of liposomes in MJD transgenic animals. This reflects an altered expression of the IKRG (SEQ. ID NO 2) targeted receptor in MJD transgenic mice.
[0137] Moreover, the biodistribution of the different liposomes in the brain and peripheral organs, namely liver, spleen, heart, lung, and kidney, was assessed. For this, MJD transgenic mice intravenously injected in the tail vein with Lipo-ICG DAS, Lipo-ICG IKRG, and Lipo-ICG NT were analyzed for ICG signal in these organs. Data demonstrated an increased accumulation in the brain of 22.00% and 29.00% for Lipo-ICG DAS and Lipo-ICG IKRG, respectively, while the increase in the brain was 10.33% for Lipo-ICG NT, compared to non-injected (control) animals (black bar, red line) (Figure 8H). As for peripheral organs, the measured ICG signal in the liver presented an increase for Lipo-ICG NT of 34.67%, while the targeted liposomes had no significant alteration compared to non-injected animals (black bar, red line). In the heart, a significant 43.67% reduction was observed in the ICG signal of animals injected with Lipo-ICG DAS compared to non-injected animals (black bar, red line), and no alteration was found for Lipo-ICG IKRG and Lipo-ICG NT. The other peripheral organs, spleen, lungs, and kidneys presented no significant alteration in liposomes delivery (Figure 8H).
[0138] These results indicate that intravenous administration of DAS- or IKRG-targeted liposomes promote a preferential accumulation of the nanoparticles in the brain over time compared to nontargeted liposomes, while preventing their potentially toxic accumulation in peripheral organs such as the liver.
[0139] Subsequently, DAS-targeted liposomes encapsulating SAG were selected to be used in cotransplantation of murine neural stem cells in MJD transgenic mice to enhance the differentiation ofthese cells after transplantation, given that DAS-targeted liposomes revealed a preferential brain accumulation in MJD transgenic mice compared to IKRG-targeted liposomes, and in vitro DAS-targeted liposomes also significantly enhanced the number of NeuN+ cells, while IKRG-targeted liposomes revealed only an increase.In vivo evaluation of stealth, pH-sensitive, and brain-targeted liposomes encapsulating SAG to induce neural differentiation of murine neural stem cells (mNSC) after transplantation into MJD mouse model
[0140] Lastly, the impact of SAG-loaded, stealth, pH-sensitive, and brain-targeted liposomes to induce neural differentiation of murine neural stem cells (mNSC) after transplantation in transgenic MJD mice was evaluated. For this, animals were transplanted with GFP-expressing mNSC and 7 days after cell transplantation, animals were divided in 3 groups for administration of i) SAG 30 mg / kg, ii) DAS-targeted liposomes loaded with SAG (Lipo-DAS SAG), volume equivalent to 30 mg / kg SAG, and iii) non-targeted liposomes loaded with SAG (Lipo-NT SAG), volume equivalent to 30 mg / kg SAG (Figure 4.9). Liposomes were intravenously administered, while free SAG was administered by intraperitoneal injection. Treatments were administered 3 times every other day and animals sacrificed 6 weeks posttransplantation.
[0141] The results indicate that a low survival of the transplanted grafts was obtained for all groups. SAG 30 mg / kg, Lipo-DAS SAG, and Lipo-NT SAG, presented 1 in 5, 3 in 5, and 2 in 5, animals with grafts, respectively (Figure 9P). The expression of mature nuclear neuronal (NeuN) and astroglial (SOX9) markers were quantified in the surviving grafts, given by the co-localization with the transplanted GFP-expressing mNSC (Figure 4A-O). Thus, the percentage of graft-derived astrocytes was 0.00% for the animal treated with SAG 30 mg / kg, 23.08% for animals treated with Lipo-DAS SAG, and 16.48% for animals treated with Lipo-NT SAG (Figure 9P). Regarding the quantification of mature neurons through co-localization of NeuN+ cells with the transplanted GFP-expressing mNSC, the animals treated with SAG 30 mg / kg, Lipo-DAS SAG, or Lipo-NT SAG, presented 100.0%, 93.41%, and 70.33% NeuN+ cells, respectively (Figure 9P). These data reveal that brain-targeted liposomes are more efficient in triggering grafts differentiation compared with NT-liposomes.MATERIALS AND METHODSMaterials
[0142] Small-molecule drugs used in the context of the present disclosure, Salbutamol (Catalog No T1139) and Smoothened Agonist (Catalog No T1779) were acquired from Targetmol. Ibuprofen (14883) and Folic Acid (F7876) were acquired from Sigma. Salbutamol and Folic Acid were dissolved in dimethyl sulfoxide (DMSO), Smoothened Agonist in water, and Ibuprofen in ethanol. All drugs were stored at -20°C until use. Peptides (FITC tagged or untagged) RVG-9r (YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRR), RVG-9r-FITC, DAS (GGGGSGCLRVGGRrRrRr), DAS-FITC and IKRG (CIKRG), IKRG-FITC were synthesized and purified by high performance liquid chromatography (HPLC) to obtain a purity higher than 95% by GeneCust. The lipids 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, CAS Number: 4004-05-1), and l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, CAS Number: 816-94-4), and 2-lminothiolane (2-IT, CAS Number: 4781-83-3) were purchased from Targetmol. The lipids l,2-Dioctadecanoyl-sn-glycero-3-phosphoethanolamine-polyethileneglycol 2000-Maleimide (DSPE-PEG-Mal, CAS Number: 474922-22-0) and 1,2-Dioctadecanoyl-sn-glycero-3-phosphoethanolamine-Hydrazone-polyethileneglycol 2000 (DSPE-Hz-PEG) were obtained from Iris Biotech. Cholesterol (CHOL, CAS Number: 57-88-5) (C8667) and Sepharose CL-4B, CAS Number: 61970-08-9, (10034006755) were acquired from Avanti (Sigma). Indocyanine Green (Catalog No 1340009, CAS Number: 3599-32-4) and Rhodamine B (83689, CAS Number: 81-88-9) were acquired from Sigma.Preparation of IKRG- and DAS-coupled PEG2000 Micelles
[0143] Coupling of the targeting ligands (IKRG or DAS) to DSPE-PEG2000-Mal was done as previously described. Briefly, IKRG (SEQ. ID NO 2) and DAS (SEQ. ID NO 1) peptides were modified with the addition of thiol groups by reaction with 2-iminothiolane hydrochloride (2-IT). In this regard, IKRG or DAS freshly dissolved in HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid, CAS Number: 7365-45-9) buffer (20 mM HEPES, 145 mM NaCI, pH 8) were mixed in a ligand / 2-IT molar ratio of 1:10 and gently stirred for 1 h, in the dark at a room temperature (for example 25 °C). A lipid film of 0.26 pmol DSPE-PEG-Mal was prepared by solvent evaporation under a mild stream of Nj. This dried lipid film was then hydrated with MES (2-Morpholinoethanesulphonic acid, CAS Number: 4432-31-9) buffer (20 mM HEPES, 20 mM MES, pH 6.5), at a concentration above 2.3 pM, the critical micellar concentration of the lipid. Micelles were formed by strong vortex followed by 15 seconds heating in a water bath at 38°C, and a second vortex shaking. Then, the freshly thiolated targeting ligands were coupled to the freshly prepared DSPE-PEG-Mal micelles by a thioester linkage (ligand to micelles molar ratio of 1:1). The coupling reaction was performed overnight, in the dark at a room temperature of 25 °C with a gentle stirring of for example 50 rpm. Micelles without conjugated ligand were prepared, as controls for non-targeted micelles, by adding HEPES buffer to the micelles. The remaining free Mai groups in the micelles were quenched by the addition of p-mercaptoethanol (CAS Number: 60-24-2) at a maleimide / p-mercaptoethanol molar ratio of 1:5, under stirring for 30 min at room temperature.Preparation of liposomes
[0144] A solution containing 13 pmol of total lipid composed of DOPE:DSPC:CHOL:DSPE-Hz-PEG (37:22:33:8, mol%) in 200 pL of absolute ethanol was mixed at 65°C and vortexed. A lipid film was thenformed by solvent evaporation under a mild stream of Nj. Afterwards, the lipid film was hydrated with 300 pL ammonium sulfate (250 mM, pH 10.5) and vortexed. Upon their formation the liposomes were extruded, 21 times, in an extruder set with holder (Avanti, Sigma) through 100 nm diameter polycarbonate filters (Avanti, Sigma), and the buffer exchanged in a Sepharose CL4-B column equilibrated with HBS (HEPES Buffered Saline) buffer (20 mM HEPES with 145 mM NaCI, pH 11). Subsequently, the total lipid concentration was assessed by cholesterol quantification using Liebermann-Buchard (LB) test. The cholesterol quantification allowed the determination of the total lipid at this stage and consequently the determination of the amount of Smoothened Agonist (SAG) and micelles to be added.Encapsulation of SAG into Liposomes and targeting ligand post-insertion
[0145] Immediately after buffer exchange to HBS pH 11 (performed as previously described), SAG was encapsulated into the liposomes using pH-gradient method by adding SAG to the liposomes at 1:16 SAG / total lipid molar ratios and incubation for 1 h, at 65°C, in a water bath. Finally, the post-insertion of 4 mol % (relative to the total lipid concentration) of IKRG-coupled DSPE-PEG micelles or DSPE-PEG micelles without ligand was performed at the same time as SAG encapsulation for 1 h at 65°C, in a water bath. For DAS-targeted liposomes, the formulation was allowed to reach a room temperature of 25 °C after SAG encapsulation and 4 mol% of DAS-micelles were added and incubated for 17 h, at 39°C, in a water bath. After the ligands post-insertion, IKRG-, DAS-, or non-targeted liposomes were purified by size exclusion chromatography on a Sepharose CL-4B column, using HBS, pH 7.4, as running buffer to remove external SAG and targeting ligands as well as chemical reagents used during the liposomal preparation. Liposomes encapsulating SAG, targeted with DAS (SEQ. ID NO 1), IKRG (SEQ. ID NO 2), or non-targeted, were denominated Lipo-DAS SAG, Lipo-IKRG SAG, and Lipo-NT SAG, respectively, as described herein.Encapsulation of Rhodamine B or Indocyanine Green into Liposomes
[0146] For encapsulation of rhodamine B, the lipid film containing 13 pmol of total lipid composed of DOPE:DSPC:CHOL:DSPE-Hz-PEG (37:22:33:8, mol%) was formed as previously described. Following, the lipid film was hydrated with a solution of 10 mM of rhodamine B (self-quenched at this concentration) instead of ammonium sulfate for passive entrapment of rhodamine B inside the freshly formed liposomes. From this point on, liposomes encapsulating rhodamine B are processed as described above. Liposomes encapsulating rhodamine B, targeted with DAS, IKRG, or non-targeted, were denominated Lipo-DAS RhB, Lipo-IKRG RhB, and Lipo-NT RhB, respectively, as described herein.
[0147] To prepare liposomes encapsulating indocyanine green (ICG), the dye was previously dissolved in absolute ethanol (1 mg / mL), and added to the lipid mixture, prior to drying of the lipid film (ICG:total lipid molar ratio 1:50). The lipid film is then hydrated using HBS (pH 7.4) and processed as describedabove. Liposomes encapsulating ICG, targeted with DAS, IKRG, or non-targeted, were denominated Lipo-ICG DAS, Lipo-ICG IKRG, and Lipo-ICG NT, respectively, as described herein.Liposome Characterization
[0148] Particle size was assessed by Nanoparticle Tracking Analysis using NanoSight NS300 (Malvern) equipped with a syringe pump. For this purpose, liposomes were diluted in filtered PBS (1:1000), at a room temperature of 25 °C. The number of particles per frame was within the recommended range of 20-100 particles / frame for NanoSight NS300. Pump speed was set to 20, camera level was 12-14, and detection threshold at 3. Five 30 second videos were recorded for each sample. The size of particles was determined using NTA software 2.2. Liposomes zeta potential and polydispersity index (PDI) were measured using a Zetasizer Ultra instrument (Malvern). PDI was measured by dynamic light scattering (DLS) and zeta potential was evaluated by electrophoretic light scattering (ELS). Both measurements were performed according to standard protocols, diluting each sample in filtered PBS (1:1000), at a room of 25 °C temperature.
[0149] The quantification of DAS (SEQ. ID NO 1) or IKRG (SEQ. ID NO 2) associated with the liposomes was made with the microBCA Protein Assay Kit (Thermo Scientific) against a BSA standard curve (0, 3.1, 6.25, 12.5, 25 and 50 pg of protein) at 570 nm in a microplate reader, SpectraMax Plus 384 spectrophotometer (Molecular Devices). Post-insertion was quantified from 0.1 pmol of total lipid (quantified as described above) and calculated according to the expected amount of ligand if postinsertion was 100% efficient.
[0150] The amount of SAG entrapped inside liposomes was assessed by absorbance reading at 230 nm in a SpectraMax Plus 384 spectrophotometer (Molecular Devices) after liposomes (0.1 pmol of total lipid) disassembly in 2 mL pure ethanol in a Suprasil quartz cuvette (product code Z600172, Hellma Analytics), calculated using a SAG standard curve (5, 10, and 20 pM) dissolved in 2 mL of pure ethanol in a Suprasil quartz cuvette (product code Z600172, Hellma Analytics), and eliminating the signal from nonloaded liposomes (0.1 pmol of total lipid) also disassembled in 2 mL pure ethanol in a Suprasil quartz cuvette.
[0151] Liebermann-Buchard (LB) assay was used for cholesterol quantification. LB is a colorimetric assay were the treatment of cholesterol with a mixture of acetic acid, acetic anhydride, and sulfuric acid (35:55:10 concentration ratios v / v) elicits a blue colour. Duplicates of 5 pL of each liposome formulation were compared against a cholesterol standard curve (0, 2.5, 5, 10 and 15 pg of cholesterol) after addition of 150 pL of LB reagent per sample and incubation at 37°C for 30 min. Absorbance was measured at 625 nm in a SpectraMax Plus 384 spectrophotometer (Molecular Devices).Cell lines and cultureHuman iPSC-derived Neuroepithelial Stem Cells
[0152] Human iPSC-derived Neuroepithelial Stem Cells (hNESC), were obtained by reprogramming human fibroblasts into iPSC using lentivirus encoding for four reprogramming factors (Oct -4, Klf4, c-Myc and Sox-2). iPSC were later induced into hNESC as previously described. Cells were cultured as monolayers in Matrigel (Corning)-coated flasks at 37°C with 5% CO2 and maintained in culture medium (maintenance culture media) composed of Neurobasal medium (Invitrogen) and DMEM / F-12 (Invitrogen), in a 1:1 ratio, 1% Penicillin / Streptomycin (Invitrogen), 2 mM L-Glutamine (Invitrogen), 1:200 N-2 supplement (Gibco), 1:100 B-27 without vitamin A (Gibco), 150 pM Ascorbic Acid (Sigma-Aldrich), 3 pM CHIR 99021 (Axon-Medchem), and 0.75 pM Purmorphamine (PMA) (Enzo) and were split every 5-7 days using Accutase (Sigma).Neural cell cultures differentiated from hNESC
[0153] hNESC were differentiated into glia and neurons as previously reported. Briefly, hNESC were plated in Matrigel (Corning)-coated coverslips in MW12 plates, 3xl05cells per well in culture media composed of Neurobasal medium (Invitrogen) and DMEM / F-12 (Invitrogen), in a 1:1 ratio, 1% Penicillin / Streptomycin (Invitrogen), 2 mM L-Glutamine (Invitrogen), 1:200 N-2 supplement (Gibco), 1:100 B-27 without vitamin A (Gibco), 250 pM Dibutyryl cyclic-AMP sodium salt (dbcAMP) (BIOLOG), 5 pM Forskolin (TargetMol), and 2 pM retinoic acid (Sigma). Cells were allowed to differentiate for one week before experiments and the culture media was changed every 3-4 days.Murine cerebellar neural stem cells (mNSC)
[0154] Murine NSC were isolated from the cerebellum of postnatal day 1 C57BI / 6 mice using methods previously described. Briefly, after dissection, batches of 10-14 tissue fragments were successively dissociated by means of a Pasteur pipette in a PBS solution with 5.5 mM glucose (Sigma), 10% Penicillin / Streptomycin (Invitrogen), with no enzymatic digestion. Cells were suspended in 10 mL of mNSC supplemented culture medium composed by DMEM-F12 / Glutamax supplemented with growth factors (10 ng / mL fibroblast growth factor-2 and 10 ng / mL epidermal growth factor), 10% Penicillin / Streptomycin (Invitrogen), and 1% B27 supplement (Gibco). The floating neurospheres were allowed to grow in uncoated 25 cm2or 75 cm2flasks and maintained at 37°C with 5% CO2.Mouse endothelial cells (bEnd.3 cell line)
[0155] The bEnd.3 cell line (ATCC number CRL-2299) is a cell line isolated from endothelioma of mice. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich) supplemented with 10% heat-inactivated FBS (Life Technologies) and 1% Penicillin / Streptomycin (Invitrogen) and cultured at 37°C under a humidified atmosphere containing 5% CO2. Cells were kept in uncoated 25 cm2or 75 cm2flasks and split every 5-7 days using Trypsin (Gibco).iPSC-derived hNESC and mNSC infection with lentivirus encoding for green fluorescent protein (GFP)
[0156] Lentiviral vectors encoding for green fluorescent protein (GFP, SIN-PGK-GFP-WHV) were produced in 293T cells using a four-plasmid system as described previously. hNESC and mNSC were transduced with lentiviral vectors encoding for GFP as previously described. Briefly, hNESC cultured in T75 Matrigel (Corning)-coated flask (3xl06cells) in 10 mL hNESC maintenance culture media were infected with lentivirus (133 ng of p24 antigen), and 24 hours later, half of the maintenance culture media was replaced to dilute the virus. On the second day, the lentiviral vectors were completely removed by changing the maintenance culture media. GFP-expression was observed 7 days after transduction. mNSC growing in neurospheres were collected by centrifugation, washed with PBS and incubated with Accutase (Sigma) for 5 min. Cells were washed in PBS and 1.5xl05cells / well in 500 pL mNSC supplemented culture medium were plated in 12 MW plates. Then, lentiviral vectors encoding GFP (the equivalent to 100 ng of p24 antigen) were added to cells 2h after plating. Twenty-four hours later, 500 pL of culture media was added and on the second day, lentiviral vectors were removed by collecting the cells by centrifugation and resuspending them in fresh culture media. GFP-expression was observed 7 days after transduction.hNESC treatment with Ibuprofen, Smoothened Agonist, Salbutamol, or Folic Acid
[0157] For resazurin reduction assay and protein and RNA extraction, hNESC were seeded in Matrigel (Corning)-coated MW6 plates at 1x10scells per well. For fluorescein diacetate (FDA) assay, 5xl04hNESC were seeded in Matrigel (Corning)-coated MW48 plates. In all cases, hNESC were seeded in maintenance culture media (described above) without the multipotency inducing factors (Ascorbic Acid, CHIR 99021, and Purmorphamine). After seeding, cells were allowed to settle for lh before being incubated with Ibuprofen (1 mM, 500 pM, 50 pM and 5 pM), Smoothened Agonist (50 nM, 5 nM, 1 nM and 0.5 nM), Salbutamol (100 pM, 50 pM, 5 pM and 0.5 pM), or Folic Acid (100 pM, 10 pM, 1 pM and 0.1 pM). A control for the highest DMSO (3-5% v / v) or ethanol (0.55% v / v) concentration for each drug used was also tested. After 3 days, the culture media was replaced for fresh culture media with the same drug concentrations. After 6 days of incubation with the drugs, cells were processed for resazurin reduction assay, protein and RNA extraction, and fluorescein diacetate (FDA) assay.Cell viabilityResazurin reduction assay
[0158] Cell viability was assessed by the resazurin reduction assay. The assay measures the chemical reduction of the resazurin dye resulting from cellular metabolic activity. For this, cells were incubated with 0.1 mg / mL resazurin, diluted in the culture medium, for 4 hours at 37°C and 5% CO2. The absorbance for the reduced and oxidized species of resazurin were read at 570 nm and 600 nm,respectively, using spectrophotometer (SpectraMax Plus 384, Molecular Devices). Cell viability was calculated according to the equation: [(A570 - A600) treated cells * 100) / (A570 - A600) control cells].Fluorescein diacetate (FDA) assay
[0159] Cell viability was also assessed using the fluorescein diacetate (FDA) assay. FDA is an esterase subtract able to cross the cell membrane, that is used as a cell viability probe to measure enzymatic activity (required to activate fluorescence), and cell-membrane integrity (required for intracellular retention of the probe). This acetoxymethyl ester produces fluorescein after hydrolysis by intracellular esterases. Briefly, culture media was replaced with 0.46 pM of FDA, prepared in Hank's Balanced Salt Solution (HBSS, Sigma), and incubated for 15 minutes at 37°C and with 5% CO2. Then, the plates were taken to the Axio Observer.Zl / 7 microscope (ZEISS), pre-heated at 37°C and with 5% CO2, and 5 representative images were taken with a Plan-Apochromat 20x / 0.80 Ph 2 M27 air objective from each well for quantification. Fluorescence FDA signal (Xex493 nm and Xem517 nm, using HXP-120 laser as light source) was quantified using CellProfiler 4.2.8 software and normalized for average fluorescence intensity of controls (non-treated hNESC).Reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR)
[0160] After treatments, cell cultures were washed 3 times with PBS and kept at -80°C until processing. RNA was extracted using the NucleoSpin RNA kit (Macherey-Nagel) according to the manufacturer's instructions. The RNA purity and concentration were measured with NanoDrop 2000 (Thermo Scientific). Then, 1000 ng of total RNA was reverse-transcribed into cDNA with iScript cDNA Synthesis Kit (Bio-Rad), according to the manufacturer's instructions. Quantitative real-time PCR was performed with the SsoAdvanced SYBR Green Supermix Kit (Bio-Rad) using cDNA diluted 10 times in DNase-free water (Sigma) according to the protocol: a single cycle of 95°C for 30 seconds followed by 39 or 45 cycles of two steps, one step of 5 seconds at 95°C followed by a step of 15 seconds at a temperature depending on the annealing temperature of each primer set (Table 4), using the CFX96 Touch PCR detection system (Bio-Rad). The CFX Maestro software (Bio-Rad) created automatically a threshold cycle (CT) for each gene. In each experiment, and for all genes, a standard curve was made, and no template and no reverse transcriptase controls were performed. Subsequently, the software to determine the PCR amplification efficiency and R2was used. The mRNA relative quantification with respect to control samples was determined by the Pfaffl method taking into consideration the different amplification efficiencies of all genes.Table 4. Primers for RT-qPCR; KPP: KiCqStart Pre-designed Primers; Fwd: primer forward; Rev: primer reverse.Gene Brand Sequence / reference Annealing temperature TUBBS Invitrogen Fwd: GGCCAAGGGTCACTACACG 58°C Rev: GCAGTCGCAG I l l i CACACTCMAP2 Invitrogen Fwd: CGAAGCGCCAATGGATTCC 57°C Rev: TGAACTATCCTTGCAGACACCTN0TCH1 Sigma KPP; SY151100032 60°C Fwd: AAGATATGCAGAACAACAGGRev: TCCATATGATCCGTGATGTCFGF20 Sigma KPP; SY211043244-073 60°C Fwd: CAGAGAAACTTACTTCCGATGRev: TAGTGCCACAAAATACCTGPTGS2 Sigma KPP; SY240824785-064 60°C Fwd: AAGCAGGCTAATACTGATAGGRev: TGTTGAAAAGTAGTTCTGGGGUI Sigma KPP; SY211043244-077 60°C Fwd: AGATGAATCACCAAAAAGGGRev: ATATCACCTTCCAAGGGTTCGAPDH Sigma KPP; SY230208421-014 60°C Fwd: TCGGAGTCAACGGATTTGRev: CAACAATATCCACTTTACCAGAGWestern-Blot
[0161] After treatments, cells were washed twice with PBS and kept at -80°C until processing. After freezing, cells were disrupted using lysis buffer composed of 150 mM NaCI, 50 mM Tris, 5 mM EDTA, 1% Triton, 0.5% sodium deoxycholate and 0.1% SDS added freshly with protease inhibitor (Complete Mini), phosphatase inhibitor (PhosStop Easy, Roche), 1 mM Phenylmethane Sulfonyl Fluoride (PMSF) (Sigma- Aldrich) and 10 pg / mL Dithiothreitol (DTT) (Sigma-Aldrich), strong vortex and sonication for 3 cycles of 10 seconds at middle speed (40-60 kHz). For each sample, the amount of protein was quantified using Pierce BCA Protein Assay Kit (Thermo Fischer Scientific). The amount of protein loaded was 100 pg per sample. Each sample was prepared with sample buffer composed of 0.5 M Tris-HCI pH: 6.8, 30% glycerol, 10% SDS, 0.6 M DTT and 0.1 mg / mL blue bromophenol, denatured by heating at 95°C for 5 minutes and stored at -20°C until use. Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) (4% loading gel and 10% resolving gel), resolving was done at 70 V for 10-15minutes and 100 V for the rest of the run. After electrophoresis, proteins were transferred to polyvinilidene diflouride (PVDF) membranes (Millipore) previously activated by diving 1 minute in methanol, 5 minutes in water and 5 minutes in CAPS (N-cyclohexylamino-3-aminopropanesulfonic acid) / 10% methanol. Transference was performed at 0.75 A for 2-2:30 hours, at 4°C. Then, the membranes were blocked with 5% milk in TBS (Tris-Buffered Saline) with 0.1% Tween 20 (TBS-T) for 1 hour and incubated with primary antibodies (Table 5) overnight at 4°C. Next, membranes were washed three times (5, 10 and 15 minutes) with TBS-T and incubated with alkaline phosphatase linked secondary antibodies (Table 4.2) for 2 hours at room temperature. Again, the membranes were washed with TBS-T three times (5, 10 and 15 minutes) and proteins were assessed using Enhanced Chemifluorescence substrate (ECF, Amersham Bioscences) in the ChemiDoc Imaging System (Bio-Rad). The signals obtained were quantified using ImageJ software (NIH, USA). A complete list of the antibodies used is provided in Table 5. All antibodies used were diluted in 5% milk in TBS-T.Table 5. Antibodies; ICC / ICH: immunocytochemistry / immunohistochemistry; WB: Western-Blot.Protein Dilution DilutionAntibody Brand Reference Host molecular for for WBweight ICC / IHC 03 Tubulin Invitrogen 480011 Mouse 1:1000 55 kDa 1:200Synaptic Guinea- MAP2 188004 - - 1:250Systems pigGFAP DAKO Z0334 Rabbit 1:1000 50 kDa 1:400Santa Cruz Sc- GUI Mouse 1:1000 110 kDa - Biotechnology 515751MAP2 Sigma-Aldrich M1406 Mouse 1:1000 280 kDa 1:250 NeuN Millipore MAB377 Mouse - - 1:500 SOX9 Abeam abl85230 Rabbit - - 1:2000 Anti-mouse IgG,IgM (H+L)Invitrogen 31328 Goat 1:10000 - - SecondaryAntibody, APAnti-rabbit IgG,IgM (H+L)Invitrogen 31340 Goat 1:10000 - - SecondaryAntibody, APAnti-mouse Alexa Invitrogen A10042 Donkey - - 1:250Protein Dilution DilutionAntibody Brand Reference Host molecular for for WBweight ICC / IHC 568 SecondaryAntibodyAnti-mouse Alexa568 Secondary Invitrogen A11004 Goat - - 1:250 AntibodyAnti-rabbit Alexa488 Secondary Invitrogen A11015 Donkey - - 1:250 AntibodyAnti-rabbit Alexa488 Secondary Invitrogen A11008 Goat - - 1:250 AntibodyAnti-Guinea PigAlexa 647Invitrogen A21450 Goat - - 1:250 SecondaryAntibodyAnti-rabbit Alexa647 Secondary Invitrogen A21245 Goat - - 1:250 AntibodyImmunocytochemistry
[0162] Cells plated in Matrigel (Corning)-coated glass coverslips in MW12 plates, 3xl05cells per well, were washed twice with PBS, fixed with 4% paraformaldehyde (PFA) (Sigma) for 20 minutes at room temperature, washed again twice with PBS and stored at 4°C until use. Fixed cells were permeabilized with 1% Triton X-100 (Sigma), followed by 1 hour blocking with 3% bovine serum albumin (BSA) / PBS (Sigma), and overnight incubation at 4°C with primary antibodies (Table X) diluted in 3% BSA / PBS. In the following day, after washing twice with PBS, incubation with the secondary antibodies (Table 4.2) diluted in 1% BSA / PBS was performed for 2 hours at room temperature. Cell's nucleus was stained with 4', 6- diamidino-2-phenylindoline (DAPI) (1:5000, Applichem). Coverslips were mounted with Fluorescence mounting medium (Dako). Slides were then dried at room temperature for at least 24 hours and kept at 4°C until images acquisition at room temperature using a Plan-Apochromat 63x / 1.40 Oil DIC M27 objective on a Zeiss LSM 710 confocal microscope, or an Axio Imager Z2 widefield microscope (CCD monochromatic digital camera Axiocam HRm) using EC Plan- Apochromat 10x / 0.3NAor Plan-Apochromat 20x / 0.8NA air objectives. Exposure times were conserved in the experiments, images (obtained from microscopy pictures) were processed using Zen blue software (ZEISS).DAS, IKRG, and RVG-9r cellular uptake and in vitro BBB model
[0163] hNESC and differentiated neural cell cultures (hNESC differentiated into glia and neurons as previously reported123) were plated in Matrigel (Corning)-covered glass coverslips at 3xl05cells per well in MW12 plates, in the culture media described above for each cell type. hNESC were plated 24 hours prior to incubation with the targeting ligands, while differentiated neural cell cultures were allowed to differentiate for 1 week before the experiment. Ligands DAS (SEQ. ID NO 1), RVG-r9, and IKRG (SEQ. ID NO 2), tagged with fluorescein isothiocyanate (FITC), were diluted at 20 mg / mL in sterile PBS and incubated with the cells for 4 hours at the concentration of 20 pg / mL. After incubation, cells were washed with PBS, fixed using 4% PFA (Sigma) for 20 minutes at a room temperature of 25 °C, washed twice with PBS, their nucleus stained with DAPI (1:5000) for 5 min at room temperature, washed again 3 times with PBS, and slides were mounted with Fluorescence mounting medium (Dako). Slides were then dried at a room temperature of 25 °C for at least 24 hours and kept at 4°C until images acquisition using a Plan-Apochromat 63x / 1.40 Oil DIC M27 objective on a Zeiss LSM 710 confocal microscope. Exposure times were conserved in the experiments, images (obtained from microscopy pictures) were processed using Zen blue software (ZEISS). Fluorescence signal was quantified using ImageJ software (NIH, USA).
[0164] For the in vitro BBB model, mouse endothelial cell line b.END3 (2xl05cells / insert) were plated in cell culture inserts (Millicell) with 1 pm pore membrane coated with Matrigel (Corning), and allowed to grow for 4 days in their described culture media. After this, 3xl05hNESC were plated per well in Matrigel (Corning)-coated glass coverslips in MW12 plates in maintenance culture and, 24 hours after plating, the insert containing the b.END3 barrier was placed on top without culture media change. Targeting ligands were placed in the upper chamber of the insert at the concentration of 20 pg / mL to evaluate their ability to pass through the endothelial cell layer to reach hNESC. Ligands were incubated for 4 hours with the cells. After this, coverslips with the hNESC were washed with PBS, fixed with 4% PFA (Sigma) for 20 minutes at a room temperature of 25 °C, washed twice with PBS. Then, nucleus was stained with DAPI (1:5000) for 5 minutes at a room temperature of 25 °C, washed 3 times with PBS, and slides were mounted with Fluorescence mounting medium (Dako). Slides were then dried at a room temperature of 25 °C for at least 24 hours and kept at 4°C until images acquisition using a Plan-Apochromat 63x / 1.40 Oil DIC M27 objective on a Zeiss LSM 710 confocal microscope. Exposure times were conserved in the experiments, images (obtained from microscopy pictures) were processed using Zen blue software (ZEISS). Fluorescence signal was quantified using ImageJ software (NIH, USA).Evaluation of liposomes pH-sensitivity
[0165] Stealth, pH-sensitive, and brain-targeted liposomes encapsulating rhodamine B as previously described were added to MES-buffered saline at pH 7.4 or 5.5 in a MW96 black / clear bottom plate, 0.1 pmol of total lipid per well in 150 pL, and incubated at 37°C for 10 min. After incubation, florescence was measured at rhodamine B excitation peak 546 nm and emission peak 568 nm (SpectraMax Gemini EM, Molecular Devices), before and after the addition of Triton X-100 (final concentration 0.1% (vol / vol)) for total liposomes leakage. The percentage of rhodamine B leakage is calculated according to formula:IpH - 10x 100%1100 - 10where Io is the fluorescence at neutral pH (7.4), and lpHis the fluorescence intensity at acidic pH (5.5) before the addition of Triton X-100, and koo is the totally de-quenched rhodamine B fluorescence at neutral pH644after Triton X-100 was added.Assessment of liposomes cellular internalization and cargo release by confocal microscopy
[0166] hNESC were seeded on Matrigel (Corning)-coated glass coverslips in MW12 plates, 3xl05cells per well in maintenance culture media. After 24 hours, cells were kept lh at 4°C or at 37°C, prior to liposome addition. Then, cells were incubated with rhodamine B-loaded liposomes targeted with DAS (SEQ. ID NO 1), IKRG (SEQ. ID NO 2), or non-targeted liposomes (0.1 pmol total lipid), for 4 hours at 37°C or 4 °C. Afterwards, coverslips were washed with PBS, fixed using 4% PFA (Sigma) for 20 minutes at a room temperature of 25 °C, washed twice with PBS, nucleus stained with DAPI (1:5000) for 5 minutes at a room temperature of 25 °C, washed again 3 times with PBS, and slides were mounted with Fluorescence mounting medium (Dako). Slides were then dried at a room temperature of 25 °C for at least 24 hours and kept at 4 °C until images acquisition using a Plan-Apochromat 63x / 1.40 Oil DIC M27 objective on a Zeiss LSM 710 confocal microscope.Flow cytometry
[0167] To evaluate the extent of cell association and internalization (uptake) of DAS- and IKRG-liposomes or non-targeted liposomes, hNESC were incubated with fluorescent rhodamine B encapsulated in each one of the mentioned liposomes. hNESC were seeded in Matrigel (Corning)-coated 12-well plates (3xl05cells / well) in their maintenance culture media (see above). To demonstrate that the receptor-mediated internalization is temperature-dependent, cells were kept lh at 4°C or at 37°C, prior to liposomes addition. Then, cells were incubated with 0.1 pmol total lipid of the liposomes under study for 4 h at 37°C or 4°C. Subsequently, cells were detached with Accutase (Sigma) for 3-5 min at 37°C, collected in conic tubes (BD, Biosciences), washed twice with cold PBS, and resuspended in 300 pL of cold PBS. All samples were immediately analyzed in a FACS Calibur flow cytometer (BD, Biosciences).Rhodamine B fluorescence was evaluated in the FL-2 channel. The data were then analyzed by FlowJo software (BD). Cell uptake was assessed in viable cells (20000 cells / sample), these being gated based on the morphological features. The cell association efficiency of each formulation was assessed by comparing the relative fluorescence units (RFU) increase relative to non-treated cells (RFU of cells treated with the formulation under study / RFU of nontreated cells).Mice
[0168] MJD-transgenic mice (C57BI / 6 background) expressing the N-terminal-truncated human ATXN3, with 69 glutamine repeats and an N-terminal haemagglutinin (HA) epitope, driven specifically in cerebellar Purkinje cells by the L7 promoter and wild-type mice, from both genders, 4-5 weeks old (colony kept in the animal facility), and immunodeficient NOD.CB17-Prkdc scid / J female mice (NOD.SCID) (Charles River), 4-5 weeks old, were used in the context of the present disclosure. The animals were housed in a temperature-controlled room of 229C°C maintained on a 12 h I ight / 12 h dark cycle. NOD.SCID mice were housed in Ventiracks to assure sterile conditions. Food and water were provided ad libitum. The experiments involving mice were previously approved by the Responsible Organization for the Animals Welfare of the Faculty of Medicine and Center for Neuroscience and Cell Biology of the University of Coimbra (ORBEA - FMUC / CNC, Coimbra, Portugal) and were carried out in accordance with the European Community directive (86 / 609 / EEC) for the care and use of laboratory animals. The researchers received adequate training (FELASA-certified course) and certification to perform the experiments from the Portuguese authorities (Diregao Geral de Alimentagao e Veterinaria, Lisbon, Portugal).In vivo imaging system (I VIS)
[0169] For analysis of the in vivo biodistribution of liposomes, 4-5 weeks old MJD transgenic mice and their wild-type littermates were tail-vein injected with indocyanine green (ICG)-loaded liposomes targeted with DAS (Lipo-ICG DAS), IKRG (Lipo-ICG IKRG), or non-targeted (Lipo-ICG NT). The dose of liposomes injected was adjusted to each animal, being administered 8 nmol of ICG per 15 g of animal. After liposomes injection, animals were anesthetized with medetomidine / ketamine and shaved around the brain region using a Wella Contura Trimmer (Harvard Apparatus). Images were acquired using an IVIS Lumina equipment (Perkin Elmer) 15 minutes, 30 minutes, lh, 3h, 6h and 24h after injection. The imaging parameters were as follows: Xex745 nm, Xem810-875 nm, fluorescence exposure time of 3 seconds, medium binning, f / stop=2 and a field of view of 12.5 cm. For each experiment and for each time point, images of non-injected animals were first acquired to serve as baseline signal for quantification. Quantification of the ICG signal obtained was performed by drawing a region of interest around the cranium and images analyzed using Living Image software 4.3.1. For all the near infrared(NIR) fluorescent measurements, radiant efficiency units were selected since these units are normalized to the incident light.Fluorimetry
[0170] For assessment of liposomes accumulation in brain and peripheral organs, MJD transgenic mice were tail-vein injected with indocyanine green (ICG)-loaded liposomes targeted with DAS (Lipo-ICG DAS), IKRG (Lipo-ICG IKRG), or non-targeted (Lipo-ICG NT). The dose of liposomes injected was adjusted to each animal, being administered 8 nmol of ICG per 15 g of animal. Injected animals and non-injected controls were sacrificed 1 hour after intravenous injection by intracardiac perfusion with cold PBS, and brain and peripheral organs (liver, spleen, heart, lungs, and kidney) were collected for the fluorometric detection of ICG signal. For this, the organs were frozen at -80°C and kept until further processing. Then, the organs were thawed, incubated with 10 mM Tris-HCI lysis buffer at pH 7.4 with 1% Triton X-100, and macerated using SpeedMill Plus (Jena Analytik). The resulting blend was pipetted in MW96 black / clear bottom flat plates in triplicates per organ. Using a fluorimeter (SpectraMax Gemini EM, Molecular Devices), the ICG signal was determined with an excitation at 789 nm and emission at 813 nm. ICG signal was normalized for non-injected controls and compared to the signal obtained from each organ to normalize for each organ's autofluorescence signal.Stereotaxic injection of human iPSC-derived NESC (hNESC) and murine neural stem cells (mNSC)
[0171] Immunodeficient NOD.CB17-Prkdc scid / J female mice (NOD.SCID) (Charles River), 4-5 weeks old, were used. In each experiment, littermates with similar weights were caged randomly and submitted to 7 days of acclimatization before the stereotaxic surgery. For stereotaxic surgery, NOD.SCID were submitted to deep anesthesia (ketamine / medetomidine) and received a single stereotaxic injection of 1.5xl05GFP-expressing human iPSC-derived NESC prepared in 2 pL HBSS (Sigma) injected in lobule 5 of the cerebellum at a rate 0.25 pL / min with an automatic injector (Stoelting Co., Wood Dale, USA) at the following coordinates: anteroposterior: - 2.3 mm, lateral: 0 mm and ventral: - 4.0 mm, relative to lambda. The animals received 3 administrations t = 7, 9, and 11 days after surgery of SAG 30 mg / kg (prepared in saline solution 0.9% NaCI) via intraperitoneal injection. Animals were sacrificed 6 weeks after cell transplantation.
[0172] MJD-transgenic mice (C57BI / 6 background) expressing the N-terminal-truncated human ATXN3, with 69 glutamine repeats and wild-type mice, from both genders, 4-5 weeks old were used. For stereotaxic surgery, MJD-transgenic mice were submitted to deep anesthesia (ketamine / medetomidine) and received a single stereotaxic injection of 1.5xl05of GFP-expressing mNSC prepared in 2 pL HBSS (Sigma) injected in lobule 5 of the cerebellum at a rate 0.25 pL / min with an automatic injector (Stoelting Co., Wood Dale, USA) at the following coordinates: anteroposterior: - 2.3 mm, lateral: 0 mm and ventral: - 4.0 mm, relative to lambda. The animals received 3 administrations t = 7, 9, and 11 days aftersurgery of SAG 30 mg / kg (prepared in saline solution 0.9% NaCI) via intraperitoneal injection, or SAG-loaded liposomes, either targeted with DAS (SEQ. ID NO 1) or non-targeted (quantity of liposomes adjusted to SAG encapsulation efficiency to be equivalent to 30 mg / kg SAG), by intravenous administration in the tail vein. Animals were sacrificed 6 weeks after transplantation.Mice brain tissue preparation and immunohistochemistry
[0173] Animals were sacrificed by xylazine / ketamine overdosing and intracardically perfused with cold 4% PFA. Subsequently, the brains were removed and kept in 4% PFA for 24h at 4°C, then cryoprotected by incubation in 25% sucrose in PBS solution for 48h at 4°C. Finally, the brains were frozen at -80°C until further sectioning. The cerebellum was sliced in 25 pm sagittal sections using a cryostat (Thermo Fisher Scientific). Free-floating brain sections were collected in 48-well plates with PBS / 0.05 mM sodium azide and kept at 49C until processing. The brain sections were first washed three times with PBS, blocked and permeabilized for 2h in 0.1% Triton X-100 and 10% normal goat serum (NGS) / PBS at room temperature. After that, brain sections were incubated overnight at 4°C with primary antibodies (Table 4) prepared in 10% NGS / PBS. In the following day, sections were washed three times with PBS and incubated with secondary antibodies prepared in 2% NGS / PBS for 2h at a room temperature of 25 °C. Then, brain sections were washed three times with PBS and nucleus was stained with DAPI (1:5000) for 10 minutes at a room temperature of 25 °C. Sections were washed three times with PBS and mounted on gelatinized glass slides. After drying, slides were mounted with Fluorescence mounting medium (Dako). Widefield fluorescence images were acquired with an Axio Imager Z2 microscope (CCD monochromatic digital camera Axiocam HRm) using EC Plan-Apochromat 10x / 0.3NA or Plan-Apochromat 20x / 0.8NA air objectives. Confocal fluorescence images were obtained with an LSM 710 Axio Observer using Plan-Apochromat 20x / 0.8NA air objective and Plan-Apochromat 40x / 1.4NA DIC m27 oil objective. For mature neurons (NeuN+) and astrocytes (SOX9+) quantification in graft-derived cells, Z-stack and tile confocal microscopy images were acquired with the Plan-Apochromat 40x / 1.4NA DIC m27 oil objective in an LSM 710 Axio Observer with exposure times conserved in the experiments. ZEN blue software (ZEISS) was used to acquire the images and for their processing. Quantification was then performed by assessing the presence of NeuN-expressing neurons or SOX9-expressing astrocytes co-localized with GFP-expressing grafted cells using the Arivis Pro software (ZEISS).Statistical analysis
[0174] All data are presented as mean ± SEM. Graphs and statistical analysis were performed in Graph Pad Prism 9 software. Statistical significance was assessed by unpaired t-test, One-way ANOVA, and Two-way ANOVA; values of p < 0.05 were considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 as indicated in the legend of the figures).00175] In an embodiment, the sequences disclosed herein are selected from Table 6.Table 6. Sequences of the present disclosure.Molecule QualifierSeq. ID NO: Seq. name Organism name Residuestype Molecule Type1 DAS synthetic construct AA Protein GGGGSGCLRVGGRrRrRr2 IKRG synthetic construct AA Protein CIKRG3 RVG-9r synthetic construct AA Protein YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRR 4 TUBB3 forward synthetic construct RNA Other RNA GGCCAAGGGTCACTACACG5 TUBB3 reverse synthetic construct RNA Other RNA GCAGTCGCAG I l l i CACACTC6 MAP2 forward synthetic construct RNA Other RNA CGAAGCGCCAATGGATTCC7 MAP2 reverse synthetic construct RNA Other RNA TGAACTATCCTTGCAGACACCT8 NOTCH1 forward synthetic construct RNA Other RNA AAGATATGCAGAACAACAGG9 NOTCH1 reverse synthetic construct RNA Other RNA TCCATATGATCCGTGATGTC10 FGF20 forward synthetic construct RNA Other RNA CAGAGAAACTTACTTCCGATG11 FGF20 reverse synthetic construct RNA Other RNA TAGTGCCACAAAATACCTG12 PTGS2 forward synthetic construct RNA Other RNA AAGCAGGCTAATACTGATAGG13 PTGS2 reverse synthetic construct RNA Other RNA TGTTGAAAAGTAGTTCTGGGMolecule QualifierSeq. ID NO: Seq. name Organism name Residues type Molecule Type14 GLI1 forward synthetic construct RNA Other RNA AGATGAATCACCAAAAAGGG 15 GLI1 reverse synthetic construct RNA Other RNA ATATCACCTTCCAAGGGTTC 16 GAPDH forward synthetic construct RNA Other RNA TCGGAGTCAACGGATTTG 17 GAPDH reverse synthetic construct RNA Other RNA CAACAATATCCACTTTACCAGAG
[0176] Methods for the alignment of sequences for comparison are well known in the art, such methods include GAP, BESTFIT, BLAST, FASTA and TFASTA. GAP uses the algorithm of Needleman and Wunsch ((1970) J Mol Biol 48: 443-453) to find the global (over the whole the sequence) alignment of two sequences that maximizes the number of matches and minimizes the number of gaps. The BLAST algorithm (Altschul et al. (1990) J Mol Biol 215: 403-10) calculates percent sequence identity and performs a statistical analysis of the similarity between the two sequences. The software for performing BLAST analysis is publicly available through the National Centre for Biotechnology Information (NCBI). Global percentages of similarity and identity may also be determined using one of the methods available in the MatGAT software package (Campanella et al., BMC Bioinformatics. 2003 Jul 10; 4:29. MatGAT: an application that generates similarity / identity matrices using protein or DNA sequences). Minor manual editing may be performed to optimise alignment between conserved motifs, as would be apparent to a person skilled in the art. The sequence identity values, which are indicated in the present subject matter as a percentage were determined over the entire amino acid sequence, using BLAST with the default parameters.
[0177] As used in the specification and claims, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a sample" includes a plurality of samples, including mixtures thereof.
[0178] As used herein, the terms "treatment" or "treating" are used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit may refer to eradication or amelioration of symptoms or of an underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. A prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease may undergo treatment, even though a diagnosis of this disease may not have been made.
[0179] The terms "comprising", "comprises" and "comprised of" as used herein are synonymous with "including", "includes" or "containing", "contains", and are inclusive or open-ended and do not exclude additional, non-recited members, elements or method steps. The terms also encompass "consisting of" and "consisting essentially of", which enjoy well-established meanings in patent terminology.
[0180] The term "comprising" whenever used in this document is intended to indicate the presence of stated features, integers, steps, components, but not to preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
[0181] Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and / or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
[0182] The disclosure should not be seen in any way restricted to the embodiments described and a person with ordinary skill in the art will foresee many possibilities to modifications thereof. The abovedescribed embodiments are combinable.
[0183] The following dependent claims further set out particular embodiments of the disclosure.References[1] Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 2016, 36(1): 172-186.[2] Li W, Englund E, Widner H, Mattsson B, van Westen D, Latt J, et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A 2016, 113(23): 6544-6549.[3] Mendonca LS, Nobrega C, Hirai H, Kaspar BK, Pereira de Almeida L. Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice. Brain 2015, 138(Pt 2): 320-335.[4] Mendonca LS, Henriques D, Fernandes V, Moreira R, Bras J, Duarte S, et al. Graft- derived neurons and bystander effects are maintained for six months after human iPSC-derived NESC transplantation in mice's cerebella. Sci Rep 2024, 14(1): 3236.[5] Dong X. Current Strategies for Brain Drug Delivery. Theranostics 2018, 8(6): 1481- 1493.[6] Moreira R, Nobrega C, de Almeida LP, Mendonca L. Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands. J Nanobiotechnology 2024, 22(1): 260.[7] Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomedicine 2007, 2(2): 129-141.[8] Mendonga LS, Pedroso De Lima MC, Simoes S. Targeted lipid-based systems for siRNA delivery. Journal of Drug Delivery Science and Technology 2012, 22(1): 65-73.[9] Conceicao M, Mendonca L, Nobrega C, Gomes C, Costa P, Hirai H, etal. Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. Biomaterials 2016, 82: 124-137.
[0010] Mendonca LS, Moreira JN, de Lima MC, Simoes S. Co-encapsulation of anti-BCR- ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng 2010, 107(5): 884-893.
[0011] Mendonca LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simoes S. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 2010, 21(1): 157-168.
[0012] Stanton BZ, Peng LF. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst 2010, 6(1): 44-54.
[0013] Jia Y, Wang Y, Xie J. The Hedgehog pathway: role in cell differentiation, polarity and proliferation. Arch Toxicol 2015, 89(2): 179-191.
[0014] Bragina O, Sergejeva S, Serg M, Zarkovsky T, Maloverjan A, Kogerman P, etal. Smoothened agonist augments proliferation and survival of neural cells. Neurosci Lett 2010, 482(2): 81-85.
[0015] Chechneva OV, Mayrhofer F, Daugherty DJ, Krishnamurty RG, Bannerman P, Pleasure DE, et al. A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury. Cell Death Dis 2014, 5(10): el481.
[0016] Namchaiw P, Wen H, Mayrhofer F, Chechneva O, Biswas S, Deng W. Temporal and partial inhibition of GLI1 in neural stem cells (NSCs) results in the early maturation of NSC derived oligodendrocytes in vitro. Stem Cell Res Ther 2019, 10(1): TIT.
Claims
C L A I M S1. A liposomal composition comprising a plurality of pH-sensitive liposomes,each liposome comprising:an outer lipidic shell, wherein the outer lipidic shell comprises a mixture of: distearoylphosphatidylcholine (DSPC), cholesterol (CHOL), and at least a mixture of two pharmaceutical acceptable pH-sensitive lipids;an aqueous inner core comprising an active compound;at least one brain-targeting molecule having at least 90% sequence identity to at least one of the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, or mixtures thereof;wherein said brain-targeting molecule is bound to the surface of the outer lipidic shell; wherein the plurality of pH-sensitive liposomes releases the active compound at a pH in the range of 5.0 to 6.5.
2. The composition according to the previous claim, wherein the plurality of pH-sensitive liposomes releases the active compound at a pH in the range of 5.0 to 5.5.
3. The composition according to any of the previous claims, wherein the at least a mixture of two pharmaceutical acceptable pH sensitive lipids is a mixture of l,2-Dioleoyl-sn-Glycero-3- Phosphoethanolamine (DOPE) and l,2-Distearoyl-sn-Glycero-3- Phosphoethanolamine-N- [Hydrazone] Polyethylene Glycol 2000 (DSPE-Hz-PEG2000).
4. The composition according to any of the previous claims, wherein the brain-targeting molecule is selected from a list consisting of: peptide, polypeptide, antibody, aptamer, protein, cell surface ligand, or combinations thereof.
5. The composition according to any of the previous claims, wherein the peptide comprises an aminoacid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1, or SEQ ID NO: 2.
6. The composition according to any of the previous claims, wherein a molar ratio (%) of the DOPE, DSPC, CHOL, and DSPE-Hz-PEG2000 is of 37:22:33:8 (DOPE:DSPC:CHOL:DSPE-Hz-PEG2000).
7. The composition according to any of the previous claims, wherein the plurality of pH-sensitive liposomes is dispersed in an aqueous phase.
8. The composition according to any of the previous claims, wherein the active compound is selected from a list consisting of: a therapeutic molecule, a small molecule, a nucleic acid, a plasmid, an antisense oligonucleotide, a chemical compound, a virus, a protein, a peptide, a radioisotope, a radiopharmaceutical, and combinations thereof.
9. The composition according to the previous claim, wherein the active compound is selected from a list consisting of: a chemotherapy drug, a hormonal therapeutic agent, an immunotherapeutic agent, an antiviral drug, an anti-inflammatory drug, an antidepressant, an antibiotic, an anticoagulant, an antidiabetic, an analgesic, an anticancer agent, an antiepileptic, an antipsychotic, an antispasmodic, a cardiovascular agent, a depressant agent, a sedative, a stimulant agent, a painkiller agent, an antipyretic, a vasodilator, an anti-angiogenic, a cytovascular agent, a signal transduction inhibitor, a tyrosine kinase inhibitor, an anti-arrhythmic compound, a hormone, a vasoconstrictor, a steroid, or combinations thereof.
10. The composition according to the previous claim, wherein the active compound is selected from a list consisting of: salbutamol, folic acid, tideglusib, ligustrazine, 6-Bromoindirubin-3'-oxime, ibuprofen, exherin trifluoroacetate, fasudil, resveratrol, sildenafil, simvastatin, metformin, ketamine, liraglutide, smoothened agonist or combinations thereof.
11. The composition according to the previous claim, wherein the active compound is smoothened agonist.
12. The composition according to any of the previous claims, wherein the composition further comprises a gene therapy vector, and / or a contrast agent for imaging.
13. The composition according to any of the previous claims, wherein the liposome further comprises a linker between the outer lipidic shell and the at least one brain-targeting molecule; preferably wherein the linker is a covalent linker like hydrazone linkage and disulfide linkage, and / or a hydrophobic anchor like stearyl chains and PEG spacers.
14. The composition according to any of the previous claims, wherein the liposome further comprises a structural lipid selected from a list consisting of: cholestenol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-2'-hydroxybutyl ether, dipalmitoylphosphatidylcholine (DPPG), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), palmitoyloleyolphosphatidylglycerol (POPG),dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidyiethanolamine (DMPE), dielaidoylphosphatidyiethanolamine (DEPE), distearoylphosphatidyiethanolamine (DSPE), stearoyloleoylphosphatidyiethanolamine (SOPE), egg phosphatidylcholine (EPC), or combinations thereof.
15. The composition according to any of the previous claims, wherein the outer lipidic shell further comprises at least one lipid conjugated to a polymer selected from a list consisting of: poly(acryl amide), poly(vinyl pyrrolidone), poly(acryloyl morpholine), poly(2-ethyl- 2-oxazoline), poly(2- methyl-oxazoline), phosphatidyl polyglycerol, polyvinyl alcohol, polysaccharide, polyethylene glycol (PEG), polyethylene glycol containing a copolymer, or combinations thereof; preferably polyethylene glycol (PEG).
16. The composition according to the previous claim, wherein the at least one conjugated lipid is conjugated to a polyethylene glycol polymer such as: PEG-diacylglycerol (DAG), PEG- dialkyloxypropyl (DAA), PEG-ceramide (Cer), PEG-phosphatidylethanolamine, PEG-1, 2-distearoyl- snglycero-3-phosphoethanolamine (DSPE), PEG-l-methyl-4-(cis-9- dioleyl) methyl-pyridinium chloride (PEG-SAINT) or combinations thereof.
17. The composition according to the previous claims 14 to 16, wherein the plurality of pH-sensitive liposomes comprises:40-90 mol% of a structural lipid; and1-60 mol% of a combination of DOPE and DSPE-Hz-PEG2000; and10-90 mol% of DSPC; and0.1-10 mol% of the at least one brain-targeting molecule;relative to the total content of a liposome.
18. The composition according to any of the previous claims 15 to 16, wherein the average molecular weight of the polyethylene glycol polymer conjugated to the lipid ranges from 550 daltons to 10000 daltons.
19. The composition according to any of the previous claims, wherein the drug encapsulating efficiency is at least 80 % (w / w) relative to the total of lipid content.
20. The composition according to any of the previous claims, wherein the outer lipidic shell is a phospholipid bilayer shell.
21. The composition according to any of the previous claims, wherein the composition is an aqueous colloidal suspension.
22. The composition according to any of the previous claims, wherein the liposomes have a zeta potential at 25 °C ranging from -11 mV to -9 mV, measured by electrophoretic light scattering (ELS).
23. The composition according to any of the previous claims, wherein the liposomes have a size ranging from 125 nm to 135 nm, measured by nanoparticle tracking analysis (NTA).
24. The composition according to any of the previous claims, wherein the liposomes have a polydispersity index lower than 0.3, measured by dynamic light scattering (DLS); preferably ranging from 0.12 to 0.25.
25. The composition according to any of the previous claims for use in medicine.
26. The composition according to any of the previous claims for use in the treatment of neurodegenerative diseases and injuries, demyelinating diseases, cardiovascular diseases, skin and wound repair, neurodevelopmental disorders, cancer, or developmental defects.
27. The composition according to the previous claim for use in the treatment of protein misfolding disorders, protein aggregation disorders, tauopathies, synucleinopathies, polyglutamine disorders, amyloid-related neurodegenerative disorders, motor neuron degenerative diseases, dementias associated with neurodegeneration, basal ganglia neurodegenerative disorders, cerebellar neurodegenerative disorders, movement-related neurodegenerative disorders, age-related neurodegenerative disorders, neuroinflammatory neurodegenerative disorders, mitochondrial dysfunction-associated neurodegenerative disorders, lysosomal dysfunction-associated neurodegenerative disorders, genetic neurodegenerative disorders of the central nervous system, progressive neurodegenerative disorders affecting the brain, central nervous system degenerative diseases, chronic neurodegenerative disorders, or adult-onset neurodegenerative diseases.
28. The composition according to the previous claim 27 for use in the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, frontotemporal dementia, multiple system atrophy, dementia with Lewy bodies, spinocerebellar ataxias, Machado-Joseph disease, progressive supranuclear palsy, or corticobasal degeneration.
29. The composition according to any of the previous claims, wherein the composition is administered with at least one more active compound.
30. The composition according to the previous claim, wherein the at least one more active compound is selected from a list consisting of: neuroprotective agents, anti-inflammatory agents, antioxidant agents, anti-apoptotic agents, protein aggregation inhibitors, tau phosphorylation inhibitors, amyloid-beta targeting agents, alpha-synuclein targeting agents, cholinergic agents, glutamatergic modulators, dopaminergic agents, mitochondrial stabilizers, autophagy inducers, gene expression modulators, nucleic acids, biologies, or combinations thereof.
31. The composition according to any of the previous claims, wherein the composition is administered at least once a month.
32. The composition according to any of the previous claims, wherein the composition is administered at least once a day.
33. The composition according to any of the previous claims, wherein the composition is administered every other day for a period of at least 5 days.
34. The composition according to any of the previous claims, wherein the composition is administered to improve cell therapy outcome.
35. The composition according to any of the previous claims, wherein the composition is administered to improve engraftment of neural stem cells, and / or neuronal progenitor cells, and / or neuroepithelial stem cells, and / or neural progenitor cells.
36. The composition according to any of the previous claims, wherein the composition is administered to improve treatment of cancer stem cells, preferably to increase cell differentiation and / or cell death and / or cell arrest.
37. A method for obtaining the plurality of pH-sensitive liposomes of the composition according to any of the previous claims, comprising the following steps:providing a lipidic mixture composed of DOPE, DSPC, CHOL, and DSPE-Hz-PEG; preferably in a molar ratio of 37:22:33:8 (DOPE:DSPC:CHOL:DSPE-Hz-PEG);dissolving the lipidic mixture in ethanol and forming a lipid film by solvent evaporation; hydrating the obtained lipid film with an ammonium sulfate solution to form liposomes;encapsulating the active compound into the liposomes obtained in the previous step, at a molar ratio of 1:16 (active compound:total lipid content of the liposomes obtained);post-inserting the brain-targeting molecule coupled to DSPE-PEG2000-micelles into the liposomes in an amount of 4 mol%, relative to the total lipid content of the liposomes;obtaining the plurality of pH-sensitive liposomes.
38. A method of treating a neurodegenerative disease, an injury, a demyelinating disease, a cardiovascular disease, a skin and wound repair, a neurodevelopmental disorder, cancer, or a developmental defect, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition according to any of the claims 1 to 37.
39. Use of the composition according to any of the previous claims 1 to 37 in the manufacture of a medicament for the treatment of a neurodegenerative disease, an injury, a demyelinating disease, a cardiovascular disease, skin and wound repair, a neurodevelopmental disorder, cancer, or a developmental defect.
40. Smoothened Agonist for use in the treatment of neurodegenerative diseases.
